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ABSTRACT
PHOTOCHEMICAL TOOLS FOR FLUORESCENT LABELING OF ENDOGENOUS
PROTEINS

SEPTEMBER 2015
STEPHEN T. MCCARRON
B.S., SIENA COLLEGE
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Assistant Professor James J. Chambers

The study of the dynamic movements of membrane bound proteins is typically
achieved through an exogenously applied fluorescent tag or genetic modification of a
receptor of interest to spatiotemporally monitor protein location. Techniques often used
for labeling proteins include overexpression of a fluorescent protein such as GFP fused to
a target protein or the application of antibodies. These methods benefit from superb
specificity towards a receptor of interest, but may impose unforeseen consequences when
studying natural protein movements. Thus, it is advantageous to development small,
modular probes that would allow for visualization of endogenous membrane bound
receptors in a minimally perturbed state.
Several strategies employing photochemical small molecules were pursued to
label important neuronal receptor targets on live cells. One method, photoaffinity
labeling, requires a highly specific ligand outfitted with a UV photoreactive group and an
orthogonal handle to covalently bind the ligand to the receptor for experimental analysis
of the target. Using this technique we synthesized high affinity photoaffinity labels to
vi

study sigma receptors, which are believed to be involved in several neurodegenerative
disorders and cancer pathologies.
Another method is fluorescently tethered small molecule ligands that utilize a
pharmacophore covalently bound to a fluorophore for specificity and subsequent
visualization of a receptor of interest. We have designed small, minimally-perturbing
modular probes that enable labeling and subcellular visualization of endogenous
receptors on live cells. This technology allows for silent labeling of a receptor of interest,
which allows for the receptor to be tagged with a fluorescent moiety in a non-ligated and
thus active state. Using these probes we labeled the presynaptic dopamine and serotonin
transporters and NMDA receptors on live cells.
Finally, we have developed a method for facile alkylation of biological substrates
utilizing a small, photoactivatable, electrophilc moiety that is compatible with aqueous
buffer. We demonstrated that the molecule is reactive only in the presence of UV light,
which gives the user temporal control over the alkylation of a nucleophile.
In sum, these small molecule probes will provide chemical biologists novel tools
for labeling membrane-bound receptors to visualize their location and trafficking, which
will give fundamental insight into their endogenous activity.
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CHAPTER 1
GENERAL LABELING STRATEGIES

1.1 Introduction
The use of fluorescent molecules has revolutionized the way we can observe
proteins, receptors, and ion channels in and on cells. These molecules have allowed for
the study of several membrane bound proteins that can give insight into not only the
structure of the protein, but function as well. Techniques that are widely used to label
membrane bound proteins include overexpression of a fluorescent protein fused to a
target protein or the application of antibodies1. Overexpression of a fluorescent protein
generally relies on a gene construct being introduced to a target cell that encodes the gene
of interest with the fusion protein. In addition, hybrid chemical/genetic strategies such as
the tetracysteine FlAsH/ReAsH or the tetraserine RhoBo systems have also been
developed2,3. Enzyme catalyzed processes are also utilized for selective chemical
modification of expressed proteins, which include the use of Bir4, Lp15, SrtA6, and
phosphopantetheinyl transferases7. Although these systems benefit from the superior
specificity that is built into the system, overexpression of some fluorescent proteins are
known to cause oligomerize under certain conditions8. In addition, overexpression of
tagged monomeric subunits of heteromultimeric proteins have been shown to bias
receptor subtype composition and function, which will make it difficult to study receptors
in their natural state9.
Another widely used method for labeling native receptors is the application of
antibodies. This technique utilizes fairly large proteins to label and track the movement of
receptors. Much like the case with genetically modified proteins, antibody labeling
1

provides high specificity for a target of interest due to the evolved nature of their binding.
Unfortunately, due to the large size of the antibody coupled with the addition of a
fluorescently labeled secondary antibody, this technique may impose unforeseen
consequences on the natural movement of a receptor on the surface of a cell. This factor
is especially significant when studying neuronal receptors that are moving in and out of a
synapse, which is a distance that is not much larger than the antibody-receptor complex10.
Ideally, a labeling strategy should not only be selective towards the receptor of
interest, but also be small to be minimally perturbing to the native system. The strategy
should be modular so it can be easily adapted for numerous uses and targets. In addition,
if the method is also silent, one would be able to visualize the receptor in a non-ligated
and thus non-perturbed state. Towards these ends, new small molecule probes were
designed and synthesized for visualization of various neuronal receptors on live cells.
They were derived from carefully chosen high affinity ligands from the literature to
ensure selective labeling of the receptors of interest.
As general background for this work, two methods of small molecule labeling
will be discussed as alternatives to genetic modification or antibody labeling approaches.
First, there will be a brief description of design strategies for photoaffinity labeling,
which utilizes a ligand outfitted with a photoreactive group and orthogonal handle. Next,
the three key features for fluorescently tethered ligands will be discussed:
pharmacophore, linker, and fluorescent reporter.

Finally, the development of

multifunctional probes will be introduced, focusing on a method for silently labeling
endogenous proteins on live cells.
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1.2 Small Molecule Labeling
Fluorescently labeled small molecule ligands have become powerful tools that can
be utilized to study proteins on living cells. These probes generally consist of a high
affinity ligand covalently modified in some fashion to a fluorescent reporter for binding
and visualization of a receptor of interest, respectively11,12. There are two key advantages
that are provided by the utilization of small molecules for imaging neuronal targets. First
one must consider the minute size of a typical organic dye in comparison to the
previously mentioned genetic and antibody techniques. Organic fluorophores generally
consist of multiple conjugated and/or aromatic ring structures that are much smaller than
proteins or quantum dots. Fluorescent proteins are generally in the range of 30 kDa and 4
nm on their longest axis whereas quantum dots can be in the 15-50 nm diameter range8.
In these cases, the fluorescent label could be similar in size to the receptors of interest,
thereby increasing the likelihood of disruption to normal trafficking. Second, small
molecule probes can be applied to native systems that have not been genetically altered.
As stated earlier, genetic modification with a fluorescent protein can lead to receptor
subtype biasing as well as oligomerization, which can lead to unforeseen changes in
receptor trafficking. By applying small molecule probes to native receptors it increases
the likelihood of viewing natural movement of the protein. The combination of the
diminutive size of organic fluorophores coupled with recent advances in imaging
techniques makes for an unprecedented confluence that allows us to study neuronal
receptor dynamics in detail that was not possible just a few years ago 13. Two small
molecule techniques that will be discussed in the following chapters to label neuronal
receptors are photoaffinity labeling and fluorescently tethered ligands.
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1.2.1 Photoaffinity Labeling
Photoaffinity labeling (PAL), a technique that was developed more than five
decades ago14, is a valuable small molecule tool that can be used to study the interactions
of ligands with their target proteins. PAL utilizes a ligand possessing a UV-photoreactive
group that can be incubated with a receptor of interest to form a noncovalently bound
ligand-receptor complex. Following binding, UV irradiation triggers the photoreactive
group to produce a highly reactive intermediate that will form a covalent link between the
ligand and the receptor at the binding site (Figure 1.1). In addition, photoaffinity labels
typically contain orthogonal groups to facilitate the detection and identification of the
photolabeled biomolecules. When designing photoaffinity ligands, it is important to
establish that the incorporated photoreactive group does not significantly alter the binding
affinity of the ligand towards the receptor when compared with the parent compound.
The formation of a covalent ligand-receptor complex aids the study of the receptor
because it allows for the use of more rigorous and harsher analysis tools such as SDSPAGE, HPLC, and mass spectrometry, which would normally lead to the dissociation of
the ligand-receptor complex15.

4

Figure 1.1. Cartoon depiction of PAL. The ligand will give specificity towards the
receptor of interest, which will put the photoreactive group in close proximity to the
receptor. Following irradiation with UV light the photoreactive group will create a
covalent bond with the receptor that can then be tagged utilizing the alkyne handle. The
tag can facilitate visualization of the receptor or affinity purification that will allow for
subsequent mass spectroscopy studies.
The choice of photoreactive group used to covalently link the ligand and receptor
is of critical design importance for labeling experiments. In most cases, the photolabeling
compound is a derivatized receptor agonist or antagonist. The photoreactive group is
usually synthetically inserted into the ligand of interest, however, some ligands may
contain moieties that are capable of intrinsic photoactivation such as sulfides, enones,
dienones, and halogenated compounds16. The photoreactive group should demonstrate
several of the following characteristics in order to successful label a receptor of interest.
First, the molecule chosen should be as small as possible to minimize any steric
interactions that would impact ligand-receptor binding affinity. Ideally, once a probe is
chosen, control experiments should be performed to ensure that the binding affinity of the
derivatized ligand for the receptor being studied is not significantly altered from the
5

parent compound15. Second, the half life of the photoactivated species should be short
enough to encourage covalent linkage between the photoaffinity ligand and receptor
before disassociation can occur. At the same time, the excited state of the molecule
should last long enough for the photoreactive group to remain in close contact with the
binding site so that the labeling efficiency is high. Lastly, the photoreactive group should
be capable of attacking both C-H and nucleophilic X-H bonds at an activation
wavelength that would not damage proteins15.
The most commonly used photoreactive groups for PAL studies are aryl azides,
diazirines, and benzophenone based compounds (Figure 1.2)17,18. The aryl azide and
diazirines moieties are precursors of nitrene and carbene groups, while benzophenone
based probes rely on the reactivity of aryl ketones19. Nitrene and carbene intermediates
are capable of rapidly reacting with double bonds or heteroatoms in addition to
chemically ‘inert’ aliphatic C-H bonds20. Benzophenones generate reactive triplet
carbonyl states upon irradiation with 350 nm light. They are generally more stable to
solvent than other photoreactive groups, however, they require long irradiation periods
that bears a risk for non-specific labeling21. The broad reactivity of these photoreactive
moieties allow for almost all functional groups found in biomolecules to be available for
forming covalent bonds.

Figure 1.2. General photoreactive groups utilized for PAL.

6

As mentioned previously, photoaffinity labels often contain an orthogonal handle
in addition to the photoreactive group to facilitate further study of the ligand-receptor
complex. Most often these groups are biotin, radioactive isotopes, fluorescent groups, and
alkyne moieties, which all help with the detection of a receptor in a complex matrix such
as cell lystate15. For example, after cross-linking a photoaffinity label to a receptor of
interest, an alkyne handle can be reacted with biotin-azide in a highly specific 1,3-dipolar
cycloaddition reaction. The biotin will allow for affinity purification of the labeled
receptor, which can be followed by trypsin digest and analysis by mass spectroscopy. The
coupling of receptor labeling with mass spectroscopy allows for information on receptorligand interactions to be obtained on several levels. For instance, these techniques can be
used to screen for the target of a particular ligand or drug candidate, find information of
the binding region through mass spectroscopy based sequencing, or identify specific
amino acids involved in interaction with the ligand in the binding pocket 15. The results
obtained at this level will be useful in developing 3D models of the ligand-receptor
complex, and therefore become a key component in effective structure based drug design.

1.2.2 Fluorescently tethered ligands

The first fluorescent labeling with a selective small molecule ligand that targeted
the β-adrenergic receptors was reported in 197622. In this work, the authors conjugated
the antagonist propranolol to a 9-aminoacridine fluorophore, which was then used to
label β-receptors in rat cerebellum. Since then, many more have followed, displaying that
receptor selective fluorescent ligands are powerful tools for studying receptor physiology
or pathophysiology on the cellular or subcellular level23. Fluorescent small molecule
probes have become increasingly sought after for use in the drug discovery process to
7

replace radioligands due their expense, health risks, and disposal issues23. Fluorescent
molecules not only solve many of these drawbacks, but also can provide other
advantages. Fluorescent molecules allow for real-time visualization and tracking of the
labeled receptor, which can provide information on dynamic changes like agoniststimulated receptor internalization, endocytosis, and receptor recycling24.
There are several factors that must be considered when designing small molecule
fluorescent ligands (Figure 1.3). The ligand and fluorophore must work together to not
only bind to the proper target of interest, but also provide high efficiency fluorescence for
visualization of the receptor. The pharmacophore should be potent and selective, as well
as allow for chemical functionalization via coupling to a linker and fluorophore. If there
are no easily available sites for modification, functionalization can be built into the
system by chemical means. In one such instance, Bai et al. described the synthesis of a
fluorescent molecule for the study of the cannabinoid receptor, CB225. The
pharmacophore chosen, SR144528, didn’t easily allow for a fluorophore to be conjugated
through a linker. However, the parent compound was modified to contain an alkyl
bromide group, which was followed by a substitution reaction with an amine linker for
conjugation to a near-infrared dye25. Another factor to consider is the location of the
fluorophore on the ligand chosen, which may alter affinity towards the receptor of
interest. For example, Yates et al. were interested in studying the CB2 receptor by
conjugating the fluorescent dye nitrobenzodiazole (NBD) directly to a CB2 agonist. The
new fluorescent probe lost extensive binding affinity towards CB2, which was ultimately
attributed to the addition of NBD26.
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Figure 1.3. Cartoon representation of an ideal ligand/fluorophore pairing.
Representation of a ligand that is appropriately decorated with a tethered fluorophore
bound to the protein. In this specific case, the ligand is able to bind properly in the
binding pocket due to the optimized length of the tether and fluorophore positioning. The
upper right box shows two probes that will not work for this protein. One probe is
functionalized with the tether in the wrong spot on the pharmacophore that would not
allow the pharmacophore to bind properly with the protein. The other has a tether to the
fluorophore that is too short, which would put the fluorophore too close to the protein and
not allow the pharmacophore to enter the binding pocket.
The choice of the size and composition of the linker between the pharmacophore
and fluorescent dye also plays an important role in potency as well as where the
fluorophore will be positioned in proximity to the receptor27. The ideal spacer length
should be derived from an optimization process taking into account the specific
pharmacophore, fluorophore, and the environment in which they will be applied. To date,
only a few studies have reported systematic evaluation of spacer length for the
fluorescent probe being studied28,29. In general, longer linkers have been used for bulky
fluorophores, such as near-infrared fluorophores, to reduce the likelihood of unfavorable
9

steric interactions with the target protein25,30. Another important consideration is that
lipophilicity can play a factor in contributing to non-specific binding of some reported
probes31,29 ,32. However, this issue can be circumvented through the use of polyethylene
glycol linkers33.
Finally, the chosen fluorophore should have high fluorescence intensity, be
photostable, and have the proper excitation and emission profile for system being
studied23. Fluorophores that are often used for fluorescent imaging include fluorescein,
coumarin, dansyl, cyanine, rhodamine derivatives, and NBD as mentioned previously.
More recently, there have also been several reported BODIPY based probes as well 23.
Fluorophores with excitation or emission wavelengths in the region of the visible light
spectrum where cells exhibit high levels of autofluorescence and light scattering should
be avoided to improve signal to noise ratio34. Care must also be taken to avoid any other
fluorescent markers that are already present in the cells of interest such as a GFP-tagged
protein.
Fluorescently tethered ligands can provide a multitude of valuable information
about a receptor of interest. Tight binding of these fluorescent small molecules can give
information regarding the mechanism of ligand binding, the fate of the receptor after
binding events such as internalization, and the structure of the binding pocket11,35,36.
Small molecule fluorophores have allowed for the development of pharmacological
assays on the single cell level through their combination with fluorescent techniques such
as fluorescence recovery after photobleaching, fluorescence correlation spectroscopy, and
fluorescence

resonance

energy

transfer

microscopy37.

Environment-sensitive

fluorophores such as dansyl, 4-aminophthalimide derivatives, and PRODRAN, have been
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employed to study the surrounding environments of these receptors. These molecules
exhibit low quantum yields in aqueous solution, but become much more fluorescent when
bound to a hydrophobic site in proteins or membranes28,38,39. Probes that contain red to
near infrared emitting fluorophores have potential for use in vivo studies due to their
longer excitation wavelengths, which not only allow for deeper penetration in living
tissues, but are also less damaging to the cellular environment. In addition, these
fluorophores allow for less light scattering compared to dyes with shorter excitation
wavelengths, which reduces background noise and improves sensitivity34.

1.2.3 Multifunctional small molecule probes
As previously discussed, small molecule fluorescent probes are powerful tools
that have been used to label and track membrane bound receptors. However, there are
some drawbacks to the current technology that limit their use. Due to the reliance on
maintained receptor occupancy by these probes during imaging, one would only be able
to observe receptors in a ligand bound, and thus perturbed, state. It has been shown that
persistence of receptor activation by an agonist can cause conformational changes of
several receptor types and also induce clathrin-mediated endocytosis or differential
trafficking patterns40,41,42. Ideally, a molecular probe should not only be highly specific
for a target of interest and contain a high contrast agent easily detected from the
background fluorescence, it should also be traceless with regard to the ligand binding site
to minimize the difference between the labeled and unlabeled state. Previous work in our
lab was toward the development of a small, minimally-perturbing fluorescent probe that
enabled labeling and subcellular visualization of endogenous glutamatergic α-amino-3hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on live, wild-type
11

neurons43. Nanoprobe 1 much like the small molecule probes discussed earlier, utilizes a
ligand for specificity towards AMPA receptors and a Cy3 dye for visualization (Figure
1.4).

Figure 1.4. Structure of Nanoprobe 1.

This probe exceeds the previous discussed technology because there are two key
additions to the molecule that allow for the permanent labeling of the receptor, as well as
a method for excising the ligand: a promiscuous acrylamide electrophile for crosslinking
to the receptor of interest and a photolabile nitroindoline core that facilitates the removal
of the ligand following irradiation with 365 nm light (Figure 1.5)43. The combination of
these functional groups allow for a receptor to be tagged with a fluorescent moiety in a
non-ligated and thus active state. This technology has allowed us to visualize and track
the endogenous receptor in live neurons in a time-resolved manner43,44.
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Figure 1.5. Cartoon depiction of nanoprobe labeling. Binding of the ligand (purple
rectangle) to the receptor of interest brings the acrylamide electrophile (green square) in
close proximity to a nucleophile to covalently bond the probe to the receptor. Following
irradiation with UV light to cleave the photolabile core (purple square), the ligand is
removed from the binding site to leave behind a fluorophore (red square) covalently bond
to the receptor.
The background described above is applied to several of the following chapters,
which describes the work done towards designing and synthesizing small molecule
fluorescent tools for labeling endogenous proteins. Some of these probes were used to
directly to label neuronal receptors on live cells, the results of which are described in
each appropriate section.
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CHAPTER 2
PHOTOAFFINITY LIGANDS FOR SIGMA RECEPTORS

2.1 Introduction
Sigma receptors were initially classified as a subclass of opioid receptors
proposed by Martin et al1. Further studies, however, showed that the sigma binding sites
were a distinct class of receptors located in both the central nervous system (CNS) as
well as a variety of tissues and organs. These studies demonstrated that there were at least
two types of sigma receptors; sigma 1 and sigma 2, which were distinguished based on
their affinity towards [3H]-(+)-pentazocine and [3H]-1,3-di(2-toyl)guanidine ([3H]-DTG).
Both receptors bind pentazocine whereas only the sigma 2 receptor binds DTG2.
Sigma 1 receptors reside at the endoplasmic reticulum (ER)–mitochondrion
interface called the mitochondrion-associated ER membrane (MAM). At the MAM, the
sigma 1 receptor regulates the stability of inositol 1,4,5-trisphosphate receptors, which
ensures proper Ca2+ signaling between the ER and mitochondrion3. These receptors also
regulate of the level of reactive oxygen species to control the dendritic spine arborization
in neurons. The sigma 1 receptor consists of 223 amino acids and has been cloned from
several mammalian species, which has been found to be 90% identical and have 95%
similar amino acid sequences across species3. Although the sequence of sigma 1 has been
characterized, the physiological role it plays remains largely elusive. There is increasing
evidence that links the sigma 1 receptor to neuroprotective/neuroregulatory functions as
well as to CNS pathologies such as schizophrenia, depression, and Alzheimer’s and
Parkinson’s diseases4,5,6. More recently, it has been shown that juvenile amyotrophic
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lateral sclerosis (ALS) is caused by a mutation in the gene encoding the sigma 1
receptor7.
The sigma 2 receptor, unlike sigma 1, has yet to be cloned and its exact
distribution is still not clear. Despite this, the sigma 2 receptor has been validated as a
biomarker for tumor cell proliferation and as a target for chemotherapy. Sigma 2
receptors are expressed in high density of nearly all human and rodent tumor cell lines 8.
The density of these receptors in proliferating mouse mammary adenocarcinoma cells
was found to be about ten-fold higher than that in the corresponding quiescent tumor cells
both in vitro and in vivo9,10. Therefore, the sigma 2 receptor has become an attractive
target for the development of small molecule probes for diagnostic imaging of solid
tumors and as a druggable site for cancer treatment11,12,13.
At the start of our work on this project, it was clear that both sigma receptors were
interesting targets due to their involvement in various neurodegenerative diseases and the
lack of information concerning the identity of sigma 2. We sought to synthesize small
molecule probes that would allow for labeling and subsequent visualization of these
receptors in live cells. One method of small molecule labeling is the use of photoaffinity
ligands, which was described in chapter 1. Briefly, photoaffinity labeling utilizes a highly
specific ligand outfitted with a UV photoreactive group and an orthogonal handle.
Following binding to the receptor, UV irradiation produces a reactive intermediate that
covalently links the ligand to the receptor. The orthogonal handle can then be utilized for
the attachment of a tag that will facilitate the detection or purification of the labeled
receptor.
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Our first step was to identify various ligands that were potent towards the sigma
receptor and were also amendable for modification with a photoreactive group. The main
goal of the project was to synthesis photoaffinity ligands that could be used to label
sigma 1 receptors on live cells. We chose the sigma 1 receptor because it was a more
validated target, which would make it easier to determine that the ligand was reacting
with the right receptor. However, because the pharmacology of the sigma receptors tends
to overlap in several ways, we anticipated that the probe may also provide information on
the identity of sigma 2.

2.1.1 Probe design
One of the first pharmacological models used to understand structural
requirements for ligand binding to sigma receptors was developed by Glennon et al14.
The model, based on analysis of different flexible sigma 1 ligands determined that one
basic amine flanked by two hydrophobic regions was necessary for binding (Figure 2.1).
The distances between the basic amino group and the primary and secondary
hydrophobic regions should be in the range of 6-10 Å and 2.5-3.9 Å, respectively14. In
addition, the basic amino group could be a secondary or tertiary amine and each
hydrophobic region tolerates steric bulk at those positions. More recently, a 3D model
developed by Laggner et al confirmed many of the details from the original Glennon
model15.
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Figure 2.1. Glennon model for ligand binding to sigma receptors
With this model in mind, we searched through several structurally diverse ligands
with

high

affinity towards

sigma

receptors,

which

include

benzomorphans,

arylalkylamines16,17, spirocyclic compounds18, steroids19, and haloperiodol20. Of these
structures, we were most interested in the arylalkylamines and haloperiodol because we
could easily modify the phenyl rings of these compounds with a photoreactive group.
Synthetic arylalkylamine compounds that are targeted to the sigma receptors often utilize
a piperazine ring as the basic amine moiety in the compound. The addition of a
cyclohexyl ring to the piperazine moiety also appears to increase the binding affinity of
these compounds21. This information along with the structure of haloperiodol led us to
the design of two new possible photoaffinity ligands for sigma receptors (Figure 2.2). In
our proposed structures, we have utilized a piperazine ring as outlined from the previous
examples. Both ligands make use of an aryl azide photoreactive group due to its small
size and facile synthesis from an aniline precursor. We also chose to vary the position of
the alkyne handle on either structure to allow for the cyclohexyl moiety to be placed on
probe 2, which might produce a compound with higher binding affinity for the sigma
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receptors. Upon completion of the synthesis of both these compounds, we have attempted
to label the sigma 1 receptor in live cells.

Figure 2.2. Proposed structures of photoaffinity labels for sigma receptors
compared to examples of arylalkylamines and haloperiodol.

2.2 Experimental methods
2.2.1 Probe 1 synthesis
Starting with p-nitrobenzoic acid, intermediate 1 was synthesized under standard
peptide coupling conditions with EDC and HOBt. Alkylation of 1 with Boc-piperazine to
form 2 was followed by acid deprotection to yield piperazine 3. The alkyne handle was
affixed to the scaffold by reacting piperazine 3 with propargyl amine under peptide
coupling conditions to form alkyne 4. Reduction of the nitro group in alkyne 4 with tin
(II) chloride (SnCl2) produced aniline 5, which was then converted to the aryl azide under
Sandmeyer conditions to complete the synthesis of probe 1 (Scheme 2.1).
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Scheme 2.1. Synthesis of photoaffinity ligand probe 1.

2.2.2 Probe 2 synthesis
Similar to the strategy used previously, probe 2 was synthesized through the
peptide coupled intermediate 1 from p-nitrobenzoic acid. Alkylation of compound 1 with
cyclohexylpiperazine led to intermediate 6, which underwent SnCl2 reduction to yield
aniline 7. Aryl azide 8 was synthesized as previously described utilizing Sandmeyer
conditions from aniline 7. The amide of intermediate 8 was then alkylated under basic
conditions to complete the synthesis of probe 2 (Scheme 2.2).
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Scheme 2.2. Synthesis of photoaffinity ligand probe 2.
2.3 Results and Discussion
The original strategy for the synthesis of probe 1 and probe 2 was to utilize pazidobenzoic acid as the starting point for both probes. This would incorporate the
photoreactive group immediately in the synthesis and facilitate the completion of these
probes in 3-4 steps. However, following the successful peptide coupling with 3chloropropyl amine, it was found that the aryl azide moiety was not stable enough to
survive the reflux conditions needed for the subsequent alkylation with Boc-piperazine or
cyclohexylpiperzine. Therefore, the azido starting material was replaced with pnitrobenzoic acid, which would be more stable under reflux conditions and can later be
converted to an aryl azide following reduction with SnCl2.
The alkylation of the amide bond in compound 8 to yield photoaffinity ligand
probe 2 was also a reaction of particular interest. The first attempts to complete the
synthesis under mild basic conditions with potassium carbonate (K2CO3) or N,Ndiisopropylethylamine (Hunig’s base) were unsuccessful despite evidence in the literature
for this transformation22,23. However, following the addition of the stronger base
potassium tert-butoxide, alkylation of the amide bond was successful in 61% yield.
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Probe 1 and probe 2 were sent to the Psychoactive Drug Screen Program at the
University of North Carolina to evaluate their binding affinity towards the sigma
receptors. Probe 1 was found to be slightly more selective towards the sigma 2 receptor
over sigma 1, with binding affinities of 230 nM and 821 nM, respectively (Figure 2.3).
Similarly, probe 2 was more selective for sigma 2 than sigma 1, but was found to have a
much higher binding affinity towards both receptors (1.9 nM, 29 nM, respectively)
(Figure 2.4). This increase in binding affinity was likely due to the addition of the
cyclohexyl group found in compound probe 2, which agrees with literature precedent.
Probe 2 was chosen as the lead compound for receptor labeling studies due to its high
potency towards both sigma receptors.

Figure 2.3. Binding curves for photoaffinity ligand probe 1. a.) Sigma 1 binding. b.)
Sigma 2 binding
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Figure 2.4. Binding curves for photoaffinity ligand probe 2. a.) Sigma 1 binding. b.)
Sigma 2 binding

To demonstrate specific labeling of the sigma receptors with probe 2, several
different cell lines and the lysates from these cell lines were incubated with
concentrations of probe varying from 0.1 nM up to 100 μM. These cell lines included
HEK, sigma 1-transfected HEK, HeLa, sigma 1-transfected HeLa, MCF7, and primary
rat cerebellar neurons, all of which have a high level of sigma 1 and sigma 2 receptor
expression. Rat organs including the liver, brain, spine, and kidney were also incubated
with probe to visualize these receptors in whole tissues. During the course of the
experiment, some samples were irradiated with 365 nm light to crosslink the ligand its
binding partner, while others were kept in the dark. Despite the potency of probe 2 for
both sigma receptors, no significant labeling in any of these experiments was observed.
In most cases there was no difference between the irradiated and non-irradiated samples.
This could possibly be due to the aryl azide moiety not being in close enough proximity
to the receptor to form a stable covalent bond. If the aryl azide moiety is in a large
hydrophobic pocket that tolerates steric bulk, as depicted in the Glennon model, then the
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azide moiety could be facing into the pocket and react with solvent rather than the
receptor.

2.4 Conclusion
Probe 2 is a potent compound for the sigma receptors. Despite its affinity, the
probe does not provide an effective method for labeling these receptors on live cells.
Further iterations of the probe could utilize a longer linker between the piperazine moiety
and the aryl azide, which might allow for labeling of the receptor by placing the aryl
azide in closer proximity to a potential nucleophile.

2.5 Materials and Methods
2.5.1 General information
All reagents, biological and chemical, were purchased through Fisher Scientific
(Fair Lawn, NJ, USA). All reactions involving air- and moisture-sensitive reagents were
performed under an argon atmosphere using syringe-septum cap techniques. DMF and
CH2Cl2 were dried by storing over molecular sieves (4Å).

Analytical thin-layer

chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.
Compounds were detected as single spots on TLC plates and visualized using UV light
(254 or 366 nm) and ninhydrin. Merck silica gel (35–70 mesh) was used for flash
chromatography.

1

H NMR spectra were recorded on a 400 MHz Bruker NMR

spectrometer using the residual proton resonance of the solvent as the standard.
Chemical shifts are reported in parts per million (ppm). When peak multiplicities are
given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t,
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triplet; q, quartet; m, multiplet. Mass spectra were measured on a Waters ZQ device for
LRMS.

2.5.2 Synthesis of PAL for sigma receptors
Synthesis of N-(3-chloropropyl)-4-nitrobenzamide (1)
P-nitrobenzoic acid (2.0 g, 12 mmol), EDC (2.3 g, 12 mmol), and HOBt (1.8 g,
12 mmol) were dissolved in dry CH2Cl2 (15 mL) under argon and stirred for 10 minutes.
3-chloropropyl amine HCl (1.2 g, 9.2 mmol) and DIPEA (2.4 mL, 14 mmol) were
dissolved in dry CH2Cl2 (5 mL) and added dropwise to the reaction mixture. After
stirring the reaction overnight the solvent was removed and the residue was dissolved in
EtOAc (50 mL). The organic layer was washed with 0.5 HCl (50 mL), saturated aq.
NaHCO3 (2x25 mL), brine (25 mL), and dried with MgSO4. The organic layer was
removed by rotary evaporation and column chromatography was performed with 2:1
EtOAc:Hexanes as the mobile phase to yield 1.96 grams (90% yield) of an off white
solid.
1

H NMR (400 MHz, CDCl3) δ ppm 8.32 (d, J = 9.09 Hz, 2 H) 7.96 (d, J = 8.84 Hz, 2 H)

6.51 (br s, 6 H) 3.69 (dt, J = 6.06, 3.03 Hz, 4 H) 2.13 - 2.22 (m, 2 H) 2.06 (s, 1 H)
Synthesis of tert-butyl 4-(3-(4-nitrobenzamido)propyl)piperazine-1-carboxylate (2)
To a stirring solution of 1 dissolved in DMF (10 mL) was added K2CO3 (0.870 g,
6.27 mmol), KI (0.170 g, 1.05 mmol), and Boc-piperazine (0.580 g, 3.14 mmol). The
reaction mixture was heated to 80˚C and stirred under argon for 18 hours. After cooling
to room temperature the mixture was poured into H2O (20 mL) and was extracted with
EtOAc (3 x 25 mL). The combined organic layers were washed with brine (25 mL) and
dried with MgSO4. The organic layer was removed using rotary evaporation and column
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chromatography was performed using 4:1 CH2Cl2:MeOH as the mobile phase to obtain
0.492 grams (60% yield) of a white solid.
1

H NMR (400 MHz, CDCl3) δ ppm 8.30 - 8.33 (m, 2 H) 7.99 (d, J = 8.34 Hz, 2 H) 3.63

(q, J = 5.81 Hz, 2 H) 3.47 (br s, 4 H) 2.43 - 2.72 (m, 5 H) 1.89 (br. s., 2 H) 1.48 (s, 9 H)
Synthesis of 4-nitro-N-(3-(piperazin-1-yl)propyl)benzamide (3)
Boc-Piperzine 2 (0.170 g, 0.433 mmol) was dissolved in 3 M anhydrous HCl (2
mL) and stirred for 1.5 hours at room temperature. The solvent was removed via rotary
evaporation to yield 0.131 grams (92% yield) of a white solid. The compound was used
without further purification.
1

H NMR (400 MHz, CD3OD) δ ppm 8.29 - 8.37 (m, 2 H) 8.02 - 8.10 (m, 2 H) 3.47 - 3.70

(m, 10 H) 2.06 - 2.18 (m, 2 H) 1.53 - 1.61 (m, 2 H)
Synthesis of 4-nitro-N-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propyl)benzamide (4)
Piperazine 3 (0.500 g, 1.52 mmol) and DIPEA (784 μL, 4.56 mmol) was
dissolved in dry CH2Cl2 (4 mL) under argon at 0˚C. Propargyl bromide (143 μL, 1.52
mmol) dissolved in CH2Cl2 (1 mL) was then added dropwise. The solution was allowed
to warm to room temperature and stir for 16 hours. The solvent was removed in vacuo
and the residue was dissolved in EtOAc (40 mL). The organic layer was washed with
NaHCO3 (2 x 20 mL), brine (20 mL), and dried with MgSO4. The solvent was removed
via rotary evaporation to and column chromatography was performed using 4:1
CH2Cl2:MeOH as the mobile phase to give 0.188 grams (38%) of a yellow oil.
1

H NMR (400 MHz, CD3OD) δ ppm 8.30 - 8.38 (m, 2 H) 8.00 - 8.07 (m, 2 H) 3.47 (t, J =

6.95 Hz, 2 H) 2.60 - 2.72 (m, 3 H) 2.46 - 2.57 (m, 2 H) 1.79 - 1.90 (m, 2 H)
Synthesis of 4-amino-N-(3-(4-(prop-2-yn-1-yl)piperazin-1-yl)propyl)benzamide (5)
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Alkyne 4 (0.230 g, 0.670 mmol) dissolved in EtOH (5 mL) was treated with
SnCl2 (0.470 g, 2.10 mmol) and heated to reflux for 16 hours. The mixture was allowed
to cool to room temperature, poured onto ice, and was made basic with the addition of 1
N NaHCO3. The solution was carefully filtered through celite and the filter cake was
washed several times with CH2Cl2. The layers were separated and the aqueous layer was
extracted with CH2Cl2 (3x15 mL). The organic layers were combined, washed with brine
(25 mL), dried with MgSO4, and the solvent was removed via rotary evaporation to yield
73 mg (35%) of a yellow oil. The product was used without further purification.
1

H NMR (400 MHz, CD3OD) δ ppm 7.60 (d, J = 8.59 Hz, 2 H) 6.68 (d, J = 8.59 Hz, 2 H)

3.40 (t, J = 6.82 Hz, 14 H) 2.61 - 2.76 (m, 4 H) 2.46 - 2.54 (m, 2 H) 1.77 - 1.86 (m, 2 H)
Synthesis of Probe 1
To a 0˚C solution of 5 (69 mg, 0.23 mmol) dissolved in 2 N HCl (5 mL) was
added slowly a solution of NaNO2 (16 mg, 0.24 mmol) in water (300 μL). After stirring
for 15 minutes, the reaction vessel was covered with aluminum foil and a solution of
NaN3 (15 mg, 0.24 mmol) in water (600 μL) was added dropwise and the reaction was
allowed to warm to room temperature and stirred for 4 hours. The mixture was poured
slowly into H2O (10 mL), basified with 1 N NaOH, and extracted with EtOAc (3x20
mL). The combined organic layers were washed with brine, dried with MgSO4, and the
solvent was removed via rotary evaporation. Column chromatography was performed
using 4:1 CH2Cl2: MeOH as the mobile phase to obtain 60 mg (81% yield) of a yellow
product.
1

H NMR (400 MHz, CD3OD) δ ppm 7.87 (d, J = 8.84 Hz, 2 H) 7.17 (d, J = 8.84 Hz, 2 H)

3.43 (t, J = 6.95 Hz, 2 H) 2.60 - 2.74 (m, 4 H) 2.46 - 2.53 (m, 2 H) 1.79 - 1.88 (m, 2 H)

29

LCMS (ESI-TOF) Calc for C17H22N6O [M+1]; 327.40, Found: 327.41
Synthesis of N-(3-(4-cyclohexylpiperazin-1-yl)propyl)-4-nitrobenzamide (6)
To a stirring solution of 1 (0.710 g, 2.97 mmol) dissolved in dry CH3CN (20 mL)
was added K2CO3 (0.820 g, 5.94 mmol), KI (50.0 mg, 0.297 mmol), and
cyclohexylpiperzine (1.00 g, 5.94 mmol). The reaction mixture was heated to reflux and
stirred under argon for 18 hours. After cooling to room temperature the mixture was
evaporated to dryness and water (20 mL) was added to the residue. The aqueous phase
was extracted with EtoAc (3 x 25 mL) and the combined organic layers were washed
with brine (25 mL) and dried with MgSO4. The organic layer was removed using rotary
evaporation and. column chromatography was performed using 4:1 CH2Cl2:MeOH as the
mobile phase to yield 0.616 grams (56% yield) of a white solid.
1

H NMR (400 MHz, CDCl3) δ ppm 8.27 - 8.32 (m, 2 H) 8.02 (d, J = 8.59 Hz, 2 H) 3.62

(d, J = 5.31 Hz, 2 H) 3.51 (s, 1 H) 2.47 - 2.69 (m, 7 H) 2.22 - 2.33 (m, 1 H) 1.77 - 1.89
(m, 6 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.06 - 1.34 (m, 6 H)
Synthesis of 4-amino-N-(3-(4-cyclohexylpiperazin-1-yl)propyl)benzamide (7)
Nitro compound 6 (0.470 g, 1.26 mmol) dissolved in EtOH (15 mL) was treated
with SnCl2 (0.833 g, 3.69 mmol) and stirred at reflux for 16 hours. The mixture was
allowed to cool to room temperature, poured onto ice, and was made basic with the
addition of 1 N NaHCO3. The solution was carefully filtered through celite and the filter
cake was washed several times with CH2Cl2. The layers were separated and the aqueous
layer was extracted with CH2Cl2 (3x15 mL). The organic layers were combined, washed
with brine (25 mL), dried with MgSO4, and the solvent was removed via rotary
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evaporation to obtain 0.367 grams (84% yield) of product. The product was used in the
next step without further purification.
1

H NMR (400 MHz, CD3OD) δ ppm 7.60 (d, J = 8.59 Hz, 2 H) 6.64 - 6.71 (d, 2 H) 5.51

(s, 1 H) 3.40 (s, 2 H) 2.45 - 2.82 (m, 8 H) 2.33 (d, J = 3.03 Hz, 1 H) 1.96 (d, J = 10.61
Hz, 2 H) 1.77 - 1.89 (m, 4 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.09 - 1.37 (m, 6 H)
Synthesis of 4-azido-N-(3-(4-cyclohexylpiperazin-1-yl)propyl)benzamide (8)
To a 0˚C solution of aniline 7 (0.290 g, 0.842 mmol) dissolved in 2 N HCl (5 mL)
was added slowly a solution of NaNO2 (60.0 mg, 0.859 mmol) in water (300 μL). After
stirring for 15 minutes, the reaction vessel was covered with aluminum foil and a solution
of NaN3 (56.0 mg, 0.859 mmol) in water (600 μL) was added dropwise and the reaction
was allowed to warm to room temperature and stirred for 2 hours. The mixture was
poured slowly into water (10 mL), basified with 1 N NaOH, and extracted with EtOAc
(3x20 mL). The combined organic layers were washed with brine, dried with MgSO4, and
the solvent was removed via rotary evaporation to obtain 0.357 grams (84% yield) of a
off white solid. The product was used without further purification.
1

H NMR (400 MHz, CD3OD) δ ppm 7.86 (d, J = 8.59 Hz, 2 H) 7.16 (d, J = 8.59 Hz, 2 H)

3.44 (t, J = 6.82 Hz, 2 H) 2.43 - 2.75 (m, 8 H) 2.28 (d, J = 3.28 Hz, 1 H) 1.94 (d, J =
11.12 Hz, 2 H) 1.79 - 1.88 (m, 4 H) 1.67 (d, J = 12.63 Hz, 1 H) 1.05 - 1.37 (m, 6 H)
Synthesis of probe 2
Azido compound 8 (0.130 g, 0.350 mmol) and potassium tert-butoxide (60.0 mg,
0.525 mmol) was dissolved in dry DMF (3 mL) under argon at 0˚C. Propargyl bromide
(32.0 μL, 0.420 mmol) dissolved in DMF (0.5 mL) was then added dropwise and the
solution was allowed to warm to room temperature and stir overnight. The mixture was
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poured into water (30 mL) and extracted with EtOAc (3x25 mL). The combined organic
fractions were washed with brine (25 mL), dried with MgSO4, and the solvent was
removed via rotary evaporation. Column chromatography was performed using 4:1
CH2Cl2:MeOH as the mobile phase to yield 86 mg (61% yield) of a yellow oil.
1

H NMR (400 MHz, CDCl3) δ ppm 7.52 (br s, 2 H) 7.05 - 7.12 (m, 2 H) 5.32 (s, 1 H)

1.83 (br s, 4 H) 1.08 - 1.33 (m, 6 H)
LCMS (ESI-TOF) Calc for C23H32N6O [M+1]; 409.54, Found: 409.55
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CHAPTER 3
SILENT, FLUORESCENT LABELING OF THE DOPAMINE AND SEROTOIN
TRANSPORTERS WITH MULTIFUNCTIONAL PROBES

3.1 Introduction
As discussed previously in chapter 1, our lab has developed a small, minimally
perturbing and multifunctional probe that has allowed us to label endogenous neuronal
receptors. Nanoprobe 1, bearing a use dependant spermine ligand, was specifically design
to label and track calcium permeable AMPA receptors. To expand the use of our
nanoprobe technology, we can exploit the modular design of the probe to substitute
portions of the probe to allow it to function differently. In this work, we were particularly
interested in replacing the spermine ligand for other pharmacophores to target other
receptors of interest. Two important molecular targets that can be studied using this
method are the presynaptic dopamine and serotonin transporters.
The dopamine transporter (DAT) regulates levels of dopamine at the synapse and
is a target for widely abused psychostimulants such as cocaine and amphetamines. DAT
belongs to the SLC6 Na+/Cl- dependent transporter family, which includes the serotonin
transporter (SERT) and norepinephrine transporter1. Dopamine is an important
neurotransmitter that modulates several processes including attention, arousal, cognition,
reward, and motor activity2. However, disruption of normal dopamine signaling has been
related

to

several

neurodegenerative

diseases

including

Parkinson’s

disease3,

schizophrenia4, bipolar disorder5, and attention deficit hyperactivity disorder6. DAT is
particularly challenging to study due to the lack of an efficient antibody2 and the
difficulty to obtain neuronal cultures containing a high amount of dopaminergic neurons7.
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The SERT is an integral membrane protein expressed in neurons of the raphe
nuclei in the brain. Similar to the function of the DAT, SERT is responsible for rapid
clearance of the neurotransmitter serotonin from the synaptic cleft, thereby terminating
the chemical signal transduction in serotonergic neurons8. As a result, SERT plays a
critical role in centrally mediated functions associated with serotonin such as sleep,
mood, and appetite9. This transporter is also the primary target for selective serotonin
reuptake inhibitors and tricyclic antidepressants, which are prescribed for the treatment of
depressive disorders and anxiety10. These drugs are designed to bind to the SERT and
prevent reuptake of serotonin at the synapse back into the cell. However, despite proven
clinical success, the mechanisms underlying why these drugs are effective remains
elusive.
Previous work in the Newman lab was toward the development of two
fluorescently tethered ligands for the DAT and SERT11,12,13.

One high affinity

fluorescent probe developed by Cha et al (JHC-1-64) utilized a tropane analogue of
cocaine to enable visualization of the DAT in live cells (Figure 3.1)12. This new probe
contained a rhodamine fluorophore that had both higher photostability and quantum yield
than previously reported probes14. In addition, JHC 1-64 applied to neuronal culture
revealed a uniform distribution of the DAT labeling of somas, extensions, and
varicosities11. The Newman group also designed a fluorescent tool based off the
antidepressant drug Citalopram, which can give insight into the mechanisms underlying
depression (Figure 3.1)13. Fluorescent compound 8 was used to demonstrate the specific
labeling of SERT in a HEK293 cell line expressing hSERT with EGFP fused to the Nterminus. This effect was also blocked in the presence of a SERT inhibitor, paroxetine13.
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Figure 3.1. Fluorescently tethered probes developed in the Newman lab for the
DAT11 and SERT13

Although both ligands have proven to be useful fluorescent tools for labeling
DAT and SERT, their effectiveness is somewhat limited as they must occupy the binding
site for visualization of the receptors. As discussed previously in chapter 1, occupation of
a binding site by an agonist or antagonist can cause conformational changes or
differential trafficking patterns. In the case for the DAT, it has been determined that not
all dopamine uptake blockers are cocaine-like and could possibly prove as effective
medications without addictive liability. Understanding the mechanisms of the differences
between cocaine and non-cocaine like ligands at the DAT may enable the development of
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medications that are effective for the treatment of cocaine and methamphetamine
addiction, as well as other neuropsychiatric disorders15. Since the fluorescent compound
JHC 1-64 blocks the binding site, it would prevent other drugs such as cocaine or
methamphetamine from binding. Hence, although constitutive activity of the DAT could
be visualized, the effects of these drugs on the trafficking of DAT cannot.

3.1.1 Probe design
In collaboration with the Newman and Gether labs, we designed new fluorescent
probes for the DAT and SERT utilizing our nanoprobe technology. In this work, we have
redesigned nanoprobe 1 to label DAT and SERT by replacing the use dependant
spermine ligand with a tropane analogue of cocaine and the antidepressant drug
citalopram, respectively (Figure 3.2). Based on the previous binding data and imaging
studies conducted by the Newman lab, we believe these new ligands will give specificity
for these receptors and therefore allow for visualization on live cells. We have also
replaced the Cy3 chromophore from nanoprobe 1 with a sulfonylrhodamine dye to
display the modular nature of our nanoprobe technology. The synthesis of these probes
should allow for silent labeling of endogenous DAT and SERT and expand the toolbox
available for chemical biologists.
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Figure 3.2. Conversion of nanoprobe 1 to DAT and SERT nanoprobes.

3.2 Experimental Methods
3.2.1 Probe synthesis
Borrowing from synthetic precedent16, the probe was synthetically elaborated
commencing with the nitroindoline core to provide two orthogonal protecting groups for
further chemical modification. The tert-butyl ester of the nitroindoline core 1 was
selectively deprotected under acidic conditions to yield carboxylic acid 2. Carboxylic
acid 2 was functionalized with rhodamine-cadaverine under standard peptide coupling
conditions to form the fluorescent intermediate 3. Rhodamine intermediate 3 then
underwent basic hydrolysis to deprotect the methyl ester moiety to produce carboxylic
acid 4. Carboxylic acid 4 was treated with either dopamine ligand (MFZ-15-94) or
serotonin ligand (VK03-45) under peptide coupling conditions to complete the synthesis
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of the dopamine (SM-V-61) and serotonin (SM-V-37) nanoprobes in 30% yield for each
probe (Scheme 3.1).

Scheme 3.1. Synthesis of DAT and SERT Nanoprobes from indoline 1.
3.3 Results and Discussion
The synthesis of both the DAT and SERT nanoprobes was based on previously
prepared nanoprobe 1. The tert-butyl ester of indoline 1 could selectively be deprotected
under mild acidic conditions with trifluoroacetic acid (TFA). The peptide coupling of the
rhodamine fluorophore to carboxylic acid 2 proved to be challenging. Under standard
peptide coupling conditions with EDC and HOBt, the reaction was found to take upwards
of 3 days to produce a majority of the fluorescent intermediate 3. This could be due to
unfavorable steric interactions between carboxylic acid 2 and the rhodamine ligand,
despite the fact that a 6 carbon linker was utilized. In the future, it might be interesting to
observe the effect of linker length on the reactivity between carboxylic acid 2 and a
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rhodamine ligand. To circumvent this issue, higher equivalents of EDC and HOBt were
utilized to promote the production of intermediate 3. This not only improved the yield of
the reaction, but also lowered the reaction time to 18 hours. Completion of both
nanoprobes was done through the peptide coupling of carboxylic acid 4 with dopamine or
serotonin ligands supplied by the Newman lab. Carboxylic acid 4 proved to be more
reactive than carboxylic acid 2, likely due to less steric crowding at that position.
Upon completion of the DAT (SM-V-61) and SERT (SM-V-37) nanoprobes, they
were sent to the Gether lab in Copenhagen for experiments to collect binding data and
visualization of both receptors. We were interested in determining the binding affinity to
ensure that the steric bulk from the nanoprobe structure did not completely disrupt the
binding of either the dopamine or serotonin ligand utilized. As shown in table 3.1 and
3.2, both SM-V-61 and SM-V-37 displayed lower binding affinities towards their
respective targets when compared to the previously synthesized fluorescent ligands from
the Newman lab. However, to our delight, both nanoprobes were found to retain affinity
for the DAT and SERT (244 nM and 202 nM, respectively), which should allow for
visualization of these receptors on live cells.
Table 3.1. Binding affinity for SM-V-61 for the DAT. Uptake values were determined
from uptake inhibition experiments in transfected COS-7 cells utilizing [3H]dopamine.
Binding affinity was determined from competition binding experiments on intact COS-7
cells using [3H] CFT (2β-carbomethoxy-3β-94-fluorophenyl)tropane) as the radioligand.
Uptake (Ki nM)
Binding (Ki nM)
DAT

DAT

SM-V-61

529

244

JHC 1-64

72

44
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Table 3.2. Binding affinity for SM-V-37 for the SERT. Uptake values were determined
from uptake inhibition experiments in transfected COS-7 cells utilizing [3H]5-HT.
Binding affinity was determined from competition binding experiments on intact COS-7
cells using [3H] S-citalopram as the radioligand.
Uptake (Ki nM)
Binding (Ki nM)
DAT

DAT

SM-V-37

603

202

Compound 8

225

N/A

To demonstrate specific labeling of DAT with SM-V-61, we utilized a HEK293
cell line stably expressing hDAT with EGFP fused to the N-terminus. Cells were
incubated with 20 nM of SM-V-61 for 20 minutes at 37˚C with or without the specific
DAT inhibitor nomifensine. As shown in Figure 3.3, live cell imaging using confocal
microscopy revealed a uniform distribution of SM-V-61 (red) at the cell surface only
where EGFP-DAT (green) was seen. The labeling of DAT by SM-V-61 is completely
blocked in the presence of nomifensine as there is no fluorescence observed at the cell
surface in the red channel. In addition, the transmission image shows that there are some
cells that have not been transfected with the EGFP-DAT and SM-V-61 does not seem to
label these cells. This evidence suggests that SM-V-61 is specific towards the EGFPDAT and is not just labeling the cell surface. Another representation of EGFP-DAT
labeling by SM-V-61 is shown in Figure 3.4. These images show complete labeling of the
cell surface as displayed by the yellow color in the overlay box.
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Figure 3.3. Visualizing SM-V-61 binding to hDAT in transfected HEK293 cells.

Figure 3.4. Overlay image of EFGP-DAT labeling by SM-V-61 in HEK293 cells.
To demonstrate specific labeling of SERT with SM-V-37, similar conditions were
followed as previously discussed. A HEK293 cell line stably expressing EGFP-SERT
was incubated with 20 nM of SM-V-37 for 20 minutes in the presence or absence of a
SERT inhibitor, paroxetine. As seen previously, we observed red fluorescence from SM43

V-37 only in the areas of green fluorescence from EGFP-SERT. Receptor labeling is also
completely blocked in the presence of paroxetine, showing no fluorescence in the red
channel (Figure 3.5). These labeling results are also confirmed by the overlay image as
seen in Figure 3.6, where the yellow color can be seen evenly distribution around the cell
surface.

Figure 3.5. Visualizing SM-V-37 binding to hDAT in HEK293 cells.

Figure 3.6. Overlay image of EFGP-SERT labeling by SM-V-37 in HEK293 cells.
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The results of the fluorescent imaging of both nanoprobes suggest that they are
specific towards their targeted receptor in transfected HEK cells. The labeling is due to
the specificity of the DAT and SERT ligands employed based on the block of the red
fluorescence in the presence of an inhibitor as well as a lack of labeling observed in nontransfected cells. Currently, work is being done in the Gether lab to optimize conditions
for ligand displacement following uncaging of the nitroindoline core utilizing UV light. If
fluorescence is still observed after uncaging, this would suggest the nanoprobe is
covalently bond to the receptor of interest and the binding site should be unhindered.
Future work will be to utilize either nanoprobe to label endogenous DAT or SERT in live
neurons, enabling visualization of these receptors in their natural state.

3.4 Conclusion
The DAT and SERT nanoprobes synthesized in this work display the modular
nature of our nanoprobe technology. The addition of either a DAT or SERT ligand to the
nanoprobe scaffold maintained affinity towards either receptor (244 nm, 202 nm,
respectively) and also allowed for visualization of these receptors in transfected HEK
cells. Further studies conducted with cultured neurons will validate these probes as new
tools available for neurobiologists to study both endogenous DAT and SERT.

3.5 Materials and Methods
3.5.1 General information
All reagents, biological and chemical, were purchased through Fisher Scientific
(Fair Lawn, NJ, USA). All reactions involving air- and moisture-sensitive reagents were
performed under an argon atmosphere using syringe-septum cap techniques. DMF and
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CH2Cl2 were dried by storing over molecular sieves (4 Å).

Analytical thin-layer

chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.
Compounds were detected as single spots on TLC plates and visualized using UV light
(254 or 366 nm) and KMnO4 or ninhydrin. Merck silica gel (35–70 mesh) was used for
flash chromatography.

1

H NMR spectra were recorded on a 400 MHz Bruker NMR

spectrometer using the residual proton resonance of the solvent as the standard.
Chemical shifts are reported in parts per million (ppm). When peak multiplicities are
given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t,
triplet; q, quartet; m, multiplet. Mass spectra were measured on a Waters ZQ device for
LRMS and at the UMass Mass Spectrometry facility for HRMS.

3.5.2 Synthesis of DAT and SERT Nanoprobes
Synthesis

of

2-(6-acrylamidohexanamido)-5-(4-(2-methoxy-2-oxoethoxy)-7-

nitroindolin-1-yl)-5-oxopentanoic acid (2)
Indoline 1 (0.200 g, 0.331 mmol) was dissolved in a 10% TFA/CH2Cl2 solution (2
mL) and stirred for 12 hours at room temperature. The solvent was removed via rotary
evaporation to yield 0.202 grams (92% yield) of a yellow oil, was used in the next step
without further purification.
1

H NMR same as previously reported16

Synthesis of 5-(N-(6-(2-(6-acrylamidohexanamido)-5-(4-(2-methoxy-2-oxoethoxy)-7nitroindolin-1-yl)-5-oxopentanamido)hexyl)sulfamoyl)-2-(6-(diethylamino)-3(diethyliminio)-3H-xanthen-9-yl)benzenesulfonate (3)
Carboxylic acid 2 (41 mg, 0.075 mmol), EDC (26 mg, 0.14 mmol), and HOBt (21
mg, 0.14 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10
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minutes. Rhodamine cadaverine (45 mg, 0.069 mmol) and DIPEA (24 μL, 0.14 mmol)
were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture over 2
minutes. After stirring the reaction for 16 hours the solvent was removed via rotary
evaporation

and

column

chromatography

was

performed

utilizing

80:10:10

CH2Cl2:CH3CN:MeOH as eluent to give 50 mg (62% yield) of a purple oil.
LCMS (ESI-TOF) Calc for C58H74N8O15S2 [M+1]; 1187.38, Found: 1187.80
Synthesis

of

5-(N-(6-(2-(6-acrylamidohexanamido)-5-(4-(carboxymethoxy)-7-

nitroindolin-1-yl)-5-oxopentanamido)hexyl)sulfamoyl)-2-(6-(diethylamino)-3(diethyliminio)-3H-xanthen-9-yl)benzenesulfonate (4)
Methyl ester 3 (40 mg, 0.034 mmol) was dissolved in MeOH (1 mL) and treated
with 1 M NaOH (67 μL). The reaction mixture was stirred at room temperature for 4
hours then neutralized with 1 M citric acid (67 μL) and concentrated via rotary
evaporation. The residue was diluted with water (2 mL), acidified to pH 2 with 1 M
citric acid, and extracted with CH2Cl2 (3 x 4 mL). The organic layer was dried with
MgSO4, filtered, and the solvent removed via rotary evaporation to obtain 38 mg (96%
yield) of a purple oil. The product was used without further purification.
LCMS (ESI-TOF) Calc for C57H72N8O15S2 [M+1]; 1173.36, Found: 1173.20
Synthesis of Dopamine Nanoprobe (SM-V-61)
Carboxylic acid 4 (21 mg, 0.018 mmol), EDC (6.0 mg, 0.032 mmol), and HOBt
(5.0 mg, 0.032 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10
minutes. Dopamine ligand (MFZ15-94) (8.0 mg, 0.016 mmol) and DIPEA (11 μL, 0.063
mmol) were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture.
After stirring the reaction for 16 hours the solvent was removed via rotary evaporation
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and the product was purified by preparative-HPLC to obtain 7.9 mg (30% yield) of a
dark pink solid. (XBridge Prep C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1%
formic acid as the mobile phase. Retention time=23.89 minutes)
1

H NMR (500 MHz, CD3OD) δ ppm 8.54 (d, J = 1.68 Hz, 1 H) 8.45 (s, 8 H) 7.99 (dd, J =

7.93, 1.83 Hz, 1 H) 7.63 (d, J = 9.00 Hz, 1 H) 7.41 (d, J = 7.93 Hz, 1 H) 7.31 - 7.35 (m, 2
H) 7.09 (dd, J = 8.32, 1.91 Hz, 1 H) 6.98 - 7.03 (m, 2 H) 6.89 (d, J = 9.46 Hz, 2 H) 6.83
(d, J = 2.14 Hz, 2 H) 6.64 (d, J = 9.16 Hz, 1 H) 6.07 - 6.10 (m, 2 H) 5.51 (dd, J = 8.54,
3.51 Hz, 1 H) 4.59 (s, 2 H) 4.14 - 4.25 (m, 3 H) 3.56 (q, J = 7.12 Hz, 8 H) 3.31 (s, 3 H)
3.08 - 3.14 (m, 6 H) 2.91 (t, J = 6.87 Hz, 2 H) 2.60 (br. s., 1 H) 2.38 - 2.54 (m, 4 H) 2.25
- 2.32 (m, 2 H) 2.16 (t, J = 7.40 Hz, 3 H) 2.08 (d, J = 5.95 Hz, 1 H) 1.90 - 2.03 (m, 1 H)
1.79 - 1.88 (m, 2 H) 1.73 (d, J = 11.75 Hz, 1 H) 1.48 - 1.56 (m, 2 H) 1.31 - 1.45 (m, 11
H) 1.16 - 1.29 (m, 23 H)
LCMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+1]+ ; 1653.85, Found: 1653.90
HRMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+2]+; 827.349, Found: 827.348
Synthesis of Serotonin Nanoprobe (SM-V-37)
Carboxylic acid 4 (23 mg, 0.020 mmol), EDC (7.0 mg, 0.036 mmol), and HOBt
(6.0 mg, 0.036 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10
minutes. Serotonin ligand (VK03-45) (9.0 mg, 0.018 mmol) and DIPEA (12 μL, 0.069
mmol) were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture.
After stirring the reaction for 16 hours the solvent was removed via rotary evaporation
and the product was purified by preparative-HPLC to obtain 8.3 mg (30% yield) of a dark
pink solid. (XBridge Prep C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1%
formic acid as the mobile phase. Retention time=25.73 minutes)
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LCMS (ESI-TOF) Calc for C85H111FN11O16S2 [M+1]+ ; 1625.98, Found: 1625.8
HRMS (ESI-TOF) Calc for C82H109Cl2N12O16S2 [M+1]+; 1625.7661, Found: 1625.7643
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CHAPTER 4

DEVELOPING A MODULAR KIT FOR TRACLESS LABELING OF
ENDOGENOUS RECEPTORS

4.1 Introduction
The synthesis of the DAT and SERT nanoprobes discussed in Chapter 3 showed
how the modular design of our nanoprobe technology could be utilized to target different
receptors of interest. With an eye towards making this technique more general for other
scientists who are interested in labeling endogenous receptors, we have designed and
synthesized a new nanoprobe bearing an alkyne handle in place of a specific ligand. The
alkyne moiety allows for ligand diversity at that point by utilizing a highly specific 1,3dipolar cycloaddition reaction (click) with a ligand containing an azido linker.

In

addition, a free carboxylic acid in the molecule facilitates fluorophore diversity through
reactions with commercially available amine terminated dyes (Figure 4.1). This modular
and functional intermediate molecule allows for a vast library of compounds with
different fluorescent profiles to be synthesized in a relatively short period of time. As a
proof of concept, we functionalized a pharmacophore with an azido linker and then
reacted it with the alkyne nanoprobe scaffold. Upon successful completion of the click
reaction, the probe was then be used to fluorescently label a receptor of interest. One
particular target of interest in our lab and in the field of neurobiology are the postsynaptic
glutamatergic NMDA receptors.
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Figure 4.1. Structure of the alkyne based nanoprobe. This new probe will allow for
ligand diversity through click reactions with a pharmacophore containing an azidomoiety.
The NMDA receptor is a subtype of glutamate receptor that is believed to be
involved in processes of synaptic plasticity and memory formation1. In the hippocampus,
NMDA receptors are tetrameric complexes composed of the NR1 subunit and a mixture
of the two NR2 subunits, NR2A and NR2B, which are needed to form a functional
ionotopic receptor2. Out of the three types of glutamate receptors, NMDA receptors are
generally the most permeable to calcium ions. Thus, overactivation of these receptors
result in excitotoxic neuronal cell death due to excess calcium influx 3. It is known that
several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease,
ALS, as well as acute disorders including stroke and epilepsy, share a final common
pathway to neuronal injury due to overstimulation of glutamate receptors4. Therefore,
NMDA receptor pharmacophores have become a topic of interest for potential
therapeutic use towards these disease states.
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4.1.1 Probe design
The strategy that we employed for the synthesis of the alkyne based nanoprobe
was slightly altered from the previously discussed nanoprobe scaffolds. Previously, the
indoline scaffold was functionalized with a fluorophore first, then followed up two steps
later with the peptide coupling of a specific pharmacophore. Here, we decided to attach
our alkyne handle first, which would allow for modification with a fluorophore as the last
step. This would allow for the alkyne nanoprobe to be reacted with a variety of
fluorophores and produce an alkyne based probe with a multitude of colors and
fluorescent profiles.
In collaboration with Dr. Doug Johnson at Pfizer Neuroscience (Cambridge, MA),
we have devised a method to target NMDA receptors by utilizing a ketamine based
ligand to react with our nanoprobe. Ketamine is a well-established anesthetic drug that
has been in use for 50 years5. Ketamine acts as a non-competitive antagonist on NMDA
receptors, where it binds at the phencyclidine (PCP) binding site6. The PCP binding site
is localized within the receptor channel and partially overlaps with the magnesium
binding site. Ketamine not only blocks the open channel and reduces the mean open time;
it also decreases the frequency of channel opening by allosteric mechanisms 7. Ketamine
is often used as a racemic mixture, however, the S(+)-isomer has a 3-4 times higher
affinity than the R-enantiomer8. To date, there have been limited structure-activity
relationships for analogues of ketamine. Work by Jose et al. was aimed at the
development of ketamine ester prodrugs for use as short-acting anestetics9. Several
analogues of ketamine were synthesized by varying the length of the alkyl chain off the
amine moiety and the type of ester employed (Figure 4.2a). Although the binding affinity
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of each compound was not determined, their anesthetic effects were compared to
ketamine in a rat infusion study. The short-chain aliphatic ester analogues broadly
retained desirable anesthetic and analgesic activities, likely due to binding at the same
site as the parent compound9. In all cases, the compounds conserved the secondary amine
contained in ketamine, which is needed for a crucial interaction with asparagines in the
NMDA receptor binding site10,11,12. Using this information we envisioned synthesizing a
ketamine analogue containing an azido moiety through an extended alkyl chain (Figure
4.2b). This would conserve the basic secondary amine for binding and also extend the
pharmacophore away from the alkyne nanoprobe to reduce unfavorable steric interactions
between the receptor and probe.

Figure 4.2. Structure of ketamine analogues. a.) Ester prodrugs of ketamine9. b.)
Proposed azido analogue of ketamine
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4.2 Methods
As discussed in the previous chapter, the nitroindoline core was synthesized
following literature precedent13. The nitroindoline core 1 underwent base hydrolysis to
deprotect the methyl ester providing carboxylic acid 2. Carboxylic acid 2 was coupled to
propargyl amine using standard peptide coupling conditions to provide the alkynecontaining nanoprobe scaffold 3. Alkyne nanoprobe 3 was subsequently treated with
trifluoroacetic acid to afford carboxylic acid 4, which is the alkyne nanoprobe scaffold
that will allow for a library of these probes to be synthesized (Scheme 4.1).

Scheme 4.1. Synthesis of alkyne nanoprobe 4 from indoline core 1.
To complete the synthesis of the ketamine based nanoprobe, carboxylic acid 4
was coupled to rhodamine-functionalized cadaverine to produce fluorescent probe 5. The
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ketamine analogue was functionalized by alkylation with 1-azido-6-bromohexane to
afford compound 6, which is then reacted with fluorescent probe 5 under standard “click”
conditions to produce the final ketamine based nanoprobe SM-V-127 (Scheme 4.2).

Scheme 4.2. Synthesis of ketamine based nanoprobe to target post synaptic NMDA
receptors

4.3 Results and Discussion
The synthesis of the alkyne nanoprobe was slightly altered when compared to the
previously discussed DAT and SERT nanoprobes in Chapter 3. Here, we peptide coupled
the alkyne ligand first to allow for deprotection of the tert-butyl ester, which would leave
a free carboxylic acid that could then be reacted with any amine terminated dye.
Following base hydrolysis of the methyl ester in indoline 1, alkyne nanoprobe 2 was
synthesized through peptide coupling with propargyl amine. We chose this simple amine
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compound because a longer linker on the pharmacophore could be utilized to extend the
ligand out from the alkyne nanoprobe scaffold.
Following the synthesis of alkyne nanoprobe 4, we chose to functionalize the
probe with the sulfonyl rhodamine fluorophore utilized in the previous chapter because of
its high quantum yield and the reaction conditions for this transformation has been
optimized. Fluorescent compound 5 would allow for a multitude of nanoprobes targeting
different receptors to be synthesized rapidly through copper mediated click reactions with
pharmacophores containing an azido handle. As discussed previously, we chose to target
glutamatergic NMDA receptors by utilizing a ketamine based pharmacophore with an
azido linker, which was synthesized by alkylating (S)-2-amino-2-(2-chlorophenyl)
cyclohexanone with 1-azido-6-bromohexane. Although a primary amine undergoing an
alkylation under reflux conditions would normally be expected to proceed smoothly, the
yield for the reaction was found to be quite poor. This may be due to the amine being
bonded to a quaternary carbon, leading to unfavorable steric interactions. The addition of
KI to encourage SN2 displacement of the alkyl halide only slightly improved the yield of
the reaction. Fluorescent compound 5 was reacted with azido ketamine analogue 6 under
standard click reaction conditions using copper iodide and sodium ascorbate to produce
the ketamine based nanoprobe SM-V-127 in 61% yield. The click reaction showed an
improved yield and fewer side products observed over the previously synthesized DAT
and SERT nanoprobes discussed in Chapter 3. This successful reaction displays how a
ligand directed small molecule probe can be synthesized rapidly from the alkyne
nanoprobe scaffold.
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Labeling studies utilizing the ketamine nanoprobe were conducted on Chinese
hamster ovary (CHO) cells stably transfected with an inducible vector containing the
NR1A/NR2B NMDA receptor subunits. As discussed previously, ketamine is an open
channel blocker of NMDA receptors and will require the addition of glutamate and
glycine in order to open the binding site. The NMDA transfected cells were incubated
with 20 μM of ketamine nanoprobe SM-V-127 with or without the parent compound
ketamine and images were acquired immediately to visualize any background
fluorescence or labeling. Without any agonist added, no labeling should be seen due to
the binding site being closed to the ligand. In both cases, minimal background
fluorescence was observed for SM-V-127 in the presence or absence of ketamine, as
expected (Figure 4.3). As demonstrated in Figure 4.4, following the addition of glutamate
and glycine, distinct fluorescent labeling is observed for SM-V-127 and is completely
blocked in the presence of ketamine itself. Cell labeling can be observed with probe
concentrations as low as 100 nM and as short as 2.5 minutes following the addition of the
agonists. The imaging results suggest that labeling is due to the specificity of the
pharmacophore attached to the nanoprobe scaffold as fluorescent is blocked by the parent
compound. Further imaging studies are being conducted to determine how specific the
ketamine probe is for the NMDA receptors. This will be done by the addition of
antibodies for the NR1A/NR2B subunits following labeling with the ketamine
nanoprobe. If visualization of the antibodies and nanoprobe colocalize, it would indicate
that the nanoprobe is likely labeling NMDA receptors. In-gel fluorescence experiments
are also being run in parallel with the CHO cell labeling studies. These experiments will
also help determine how specific the ketamine nanoprobe is for the NMDA receptor as
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well as give insight into other proteins that the probe might label. Together, these results
demonstrate that an alkyne based nanoprobe can be utilized to create multifunctional
probes for receptor targeting.

Figure 4.3. Fluorescent imaging of ketamine nanoprobe SM-V-127 pre-agonist
addition.

Figure 4.4. Fluorescent imaging of ketamine nanoprobe SM-V-127 post-agonist
addition.
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4.4 Conclusion
The alkyne based nanoprobe described in this work shows that the scaffold can be
utilized to rapidly synthesize multifunctional probes to target receptors of interest. The
addition of a ketamine ligand through a click reaction with the alkyne nanoprobe allowed
for visualization of NMDA receptors in transfected CHO cells. The alkyne nanoprobe
can provide a general labeling tool available for scientists to study various membrane
bound endogenous receptors.

4.5 Materials and Methods
4.5.1 General information
All reagents, biological and chemical, were purchased through Fisher Scientific
(Fair Lawn, NJ, USA). All reactions involving air- and moisture-sensitive reagents were
performed under an argon atmosphere using syringe-septum cap techniques. DMF and
CH2Cl2 were dried by storing over molecular sieves (4Å).

Analytical thin-layer

chromatography (TLC) was carried out using Merck Silica gel 60 F254 aluminum sheets.
Compounds were detected as single spots on TLC plates and visualized using UV light
(254 or 366 nm) or ninhydrin.
chromatography.

1

Merck silica gel (35–70 mesh) was used for flash

H NMR spectra were recorded on a 500 MHz Bruker NMR

spectrometer using the residual proton resonance of the solvent as the standard.
Chemical shifts are reported in parts per million (ppm). When peak multiplicities are
given, the following abbreviations are used: s, singlet; bs, broad singlet; d, doublet; t,
triplet; q, quartet; m, multiplet.

13

C NMR spectra were proton decoupled and recorded on

a 500 MHz spectrometer using carbon signal of the deuterated solvent as the internal
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standard. Mass spectra were measured either on a Waters ZQ device for LRMS and at
the UMass Mass Spectrometry facility for HRMS.

4.5.2 Synthesis of alkyne nanoprobe
Synthesis of 2-((1-(4-(6-acrylamidohexanamido)-5-(tert-butoxy)-5-oxopentanoyl)-7nitroindolin-4-yl)oxy)acetic acid (2)
Indoline 1 (0.400 g, 0.662 mmol) was dissolved in MeOH (22 mL) and treated
with 1 M NaOH (993 μL). The reaction mixture was stirred at room temperature for 16
hours then neutralized with 1 M citric acid (993 μL) and concentrated via rotary
evaporation. The residue was diluted with H2O (10 mL), acidified to pH 2 with 1 M
citric acid, and extracted with CH2Cl2 (3 x 20 mL). The organic layer was dried with
MgSO4, filtered, and the solvent removed via rotary evaporation to yield 380 mg (97%
yield) of product. The product was used without further purification.
1

H NMR (400 MHz, CD3OD) δ ppm 7.73 (d, J = 9.09 Hz, 1 H) 6.78 (d, J = 9.09 Hz, 1 H)

6.21 - 6.24 (m, 2 H) 5.64 (dd, J = 8.34, 3.79 Hz, 1 H) 5.51 (s, 1 H) 4.30 - 4.34 (m, 2 H)
3.24 - 3.29 (m, 2 H) 3.20 (t, J = 7.96 Hz, 2 H) 2.83 (s, 2 H) 2.24 - 2.33 (m, 2 H) 1.53 1.71 (m, 5 H) 1.47 - 1.50 (s, 9 H) 1.38 - 1.45 (m, 3 H)
Synthesis of tert-butyl 2-(6-acrylamidohexanamido)-5-(7-nitro-4-(2-oxo-2-(prop-2yn-1-ylamino)ethoxy)indolin-1-yl)-5-oxopentanoate (3)
Carboxylic acid 2 (0.600 g, 1.02 mmol) and EDC (0.290 g, 1.53 mmol) were
dissolved in dry CH2Cl2 (3 mL) under argon and stirred for 10 min. Propargylamine (196
μL, 3.06 mmol) dissolved in dry CH2Cl2 (2 mL) was added slowly to the reaction mixture
and allowed to stir for 16 hours. The solvent was removed via rotary evaporation and the
residue was dissolved with EtOAc (20 mL) and washed with 1 M citric acid, aq. sat.
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NaHCO3, brine, dried with MgSO4, and the solvent removed to yield 480 mg (75% yield)
of a red oil.
1

H NMR (500 MHz, CDCl3) δ ppm 7.66 (d, J = 9.00 Hz, 1 H), 6.98 (t, J = 5.42 Hz, 1 H),

6.55 (d, J = 9.00 Hz, 1 H), 6.47 (d, J = 7.63 Hz, 1 H), 5.99 - 6.11 (m, 2 H), 5.52 (dd, J =
10.22, 1.53 Hz, 1 H), 4.57 (d, J =1.68 Hz, 2 H), 4.41 (ddd, J = 9.12, 7.67, 3.97 Hz, 1 H),
4.16 (t, J = 8.16 Hz, 2 H), 4.08 (dd, J = 5.26, 2.06 Hz, 2 H), 3.13 (d, J = 2.59 Hz, 1 H),
3.12 (t, J = 6.56 Hz, 2 H), 2.44 - 2.59 (m, 2 H), 2.11 - 2.25 (m, 4 H), 1.99 - 2.07 (m, 1 H),
1.98 (s, 1 H), 1.64 (s, 2 H), 1.51 - 1.58 (m, 2 H), 1.40 (s, 9 H), 1.26 (d, J = 7.32 Hz, 2 H),
1.19 (t, J = 7.17 Hz, 1 H).
13

C NMR (500 MHz, CDCl3) δ ppm 173.46, 171.15, 170.76, 166.87, 165.71, 156.33,

136.71, 136.05, 131.01, 126.06, 125.47, 123.33, 107.60, 82.33, 79.00, 71.78, 67.72,
60.41, 52.61, 49.90, 39.03, 35.89, 32.05, 28.86, 26.79, 26.27, 26.04, 24.69, 21.06, 14.20.
LCMS (ESI-TOF) Calc for C31H41N5O9[M+1] ; 628.69, Found: 628.50
Synthesis

of

2-(6-acrylamidohexanamido)-5-(7-nitro-4-(2-oxo-2-(prop-2-yn-1-

ylamino)ethoxy)indolin-1-yl)-5-oxopentanoic acid (4)
Alkyne 3 (0.110 mg, 0.175 mmol) was dissolved in a 10% TFA/CH2Cl2 solution
(2 mL) and stirred for 12 hours at room temperature. The solvent was removed via rotary
evaporation to yield 120 mg (98% yield) of a red oil. The product was used without
further purification.
1

H NMR (500 MHz, CD3OD) δ ppm 7.74 (d, J = 9.00 Hz, 1 H), 6.79 (d, J = 9.16 Hz, 1

H), 6.20 - 6.24 (m, 2 H), 5.64 (dd, J = 9.08, 2.98 Hz, 1 H), 4.73 (s, 2 H), 4.46 (dd, J =
9.00, 5.04 Hz, 1 H), 4.32 (t, J = 8.01 Hz, 2 H), 4.06 (d, J = 2.59 Hz, 2 H), 3.22 - 3.28 (m,
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4 H), 2.64 - 2.75 (m, 2 H), 2.62 (t, J = 2.52 Hz, 1 H), 2.27 - 2.31 (m, 3 H), 2.00 - 2.09 (m,
3 H), 1.63 - 1.70 (m, 2 H), 1.52 - 1.61 (m, 2 H), 1.36 - 1.44 (m, 2 H).
13

C NMR (500 MHz, CD3OD) δ ppm 174.96, 173.53, 171.36, 168.43, 166.72, 157.00,

136.33, 135.79, 130.70, 125.11, 124.67, 124.16, 107.65, 78.92, 70.88, 67.06, 51.78,
49.98, 38.88, 35.23, 31.50, 28.58, 27.89, 26.09, 25.07.
LCMS (ESI-TOF) Calc for C27H33N5O9[M+1] ; 572.23, Found: 572.20
Synthesis of rhodamine-alkyne nanoprobe 5
Carboxylic acid 4 (24 mg, 0.042 mmol), EDC (12 mg, 0.063 mmol), and HOBt
(10 mg, 0.063 mmol) were dissolved in dry DMF (1 mL) under argon and stirred for 10
min. Rhodamine cadaverine (27 mg, 0.042 mmol) and DIPEA (15 μL, 0.084 mmol)
were dissolved in dry DMF (1 mL) and added slowly to the reaction mixture. After
stirring the reaction for 16 hours, the solvent was removed via rotary evaporation and
column chromatography was performed utilizing 80:10:10 CH2Cl2:CH3CN:MeOH as
eluent to yield 26 mg (52% yield) of a deep purple oil.
1

H NMR (500 MHz, CD3OD) δ ppm 8.66 (s, 1 H) 8.08 - 8.14 (m, 1 H) 7.86 (d, J = 7.17

Hz, 1 H) 7.68 (d, J = 8.85 Hz, 1 H) 7.44 - 7.54 (m, 2 H) 7.12 (d, J = 9.46 Hz, 2 H) 6.99
(d, J = 9.46 Hz, 2 H) 6.92 (s, 2 H) 6.75 (d, J = 9.00 Hz, 1 H) 6.15 - 6.24 (m, 2 H) 4.68 (s,
2 H) 4.33 (d, J = 7.32 Hz, 1 H) 4.26 (t, J = 7.86 Hz, 2 H) 4.03 (s, 2 H) 3.67 (q, J = 6.56
Hz, 10 H) 3.14 - 3.25 (m, 8 H) 3.02 (t, J = 6.33 Hz, 2 H) 2.61 (d, J = 2.29 Hz, 3 H) 2.27
(t, J = 7.32 Hz, 3 H) 2.04 - 2.14 (m, 1 H) 1.95 (dd, J = 14.42, 7.10 Hz, 1 H) 1.59 - 1.67
(m, 3 H) 1.45 - 1.57 (m, 8 H) 1.25 - 1.39 (m, 20 H)
13

C NMR (500 MHz, CD3OD) δ ppm 174.74, 171.32, 168.28, 167.90, 166.62, 157.90,

156.98, 156.42, 155.70, 145.86, 142.74, 136.32, 135.71, 133.86, 132.28, 131.10, 130.78,
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127.92, 126.43, 126.32, 125.08, 124.71, 124.11, 113.87, 113.67, 107.68, 95.64, 79.03,
78.13, 77.88, 77.62, 70.95, 67.06, 53.02, 50.01, 45.49, 42.68, 38.88, 35.37, 31.56, 29.13,
28.77, 28.54, 27.96, 27.93, 27.06, 26.17, 25.92, 25.83, 25.04, 11.58
LCMS (ESI-TOF) Calc for C60H75N9O14S2 [M+1] ; 1210.42, Found: 1210.40

4.5.3 Synthesis of ketamine nanoprobe (6)
Rhodamine-alkyne nanoprobe 5 (17 mg, 0.0140 mmol) was combined with CuI
(1.2 mg, 0.0040 mmol) and sodium ascorbate (1.2 mg, 0.0040 mmol) and dissolved in
CH3CN/H2O (1 mL/0.1 mL). Ketamine azide ligand 7 (3.0 mg, 0.0094 mmol) dissolved
in CH3CN (1 mL) was then added and the reaction mixture was allowed to stir for 16
hours. The solvent was removed via rotary evaporation and the product was purified by
preparative-HPLC to obtain 8.8 mg (61% yield) of product as a pink solid. (XBridge Prep
C18 5μm (10 x 100 mm) column: H2O and CH3CN/0.1% formic acid as the mobile
phase.)
LCMS (ESI-TOF) Calc for C78H100ClN13O15S2 [M+1] ; 1559.29, Found: 1558.90
HRMS (ESI-TOF) Calc for C78H100ClN13O15S2 [M+2]+; 780.8376, Found: 780.8393

4.5.4 Synthesis of ketamine azide ligand (7)
To a suspension of K2CO3 (110 mg, 0.670) in CH3CN (3 mL) was added 2amino-2-(2-chlorophenyl)cyclohexanone (50.0 mg, 0.223 mmol) and a catalytic amount
of KI. 1-azido-6-bromohexane (55.0 mg, 0.268 mmol) dissolved in CH3CN (2 mL) was
then added dropwise and the solution was heated to reflux and stirred for 16 hours. After
cooling to room temperature the solvent was removed via rotary evaporation. H2O (10
mL) was added to the residue and was extracted with EtOAc (3 x 10 mL). The combined
64

organic layers were combined, washed with brine (10 mL), dried with MgSO4, and
evaporated via rotary evaporation. The crude material was purified by column
chromatography use 1:1 EtOAc:hexanes as eluent to yield 23 mg (30% yield) as a clear
oil.
LCMS (ESI-TOF) Calc for C18H25ClN4O[M+1] ; 349.17, Found: 349.20
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CHAPTER 5
CAGED AZIRIDINIUM-PHOTOCONTROL OVER ALKYLATION OF
NUCLEOPHILES

Adapted with permission from McCarron, S.T.; Feliciano, M.; Johnson, J.N.; Chambers,
J.J. Photoinitiated release of an aziridinium ion precursor for the temporally controlled
alkylation of nucleophiles. Bioorganic and Medicinal Chemistry Letters. 2013, 8, 23952398. Copyright 2013 Elsevier Limited. License number
3618870307317

5.1 Introduction
The development of novel and efficient methods aimed at the facile alkylation of
biological substrates has been a topic of much effort in the field of chemical biology1,2,3,4.
The application of small molecule probes to a biological target allows for subcellular
imaging and the study of dynamic protein motions in and on cells. The power of these
molecules can be synergistic with new sub-diffraction resolution microscopy methods,
which typically rely on the delivery and attachment of fluorophores to proteins of
interest5,6,7. As mentioned in previous chapters, these fluorophores are usually delivered
by one of two methods: genetic tagging of the protein of interest using a naturally
fluorescent reporter protein such as GFP or by non-covalent labeling using the tried-andtrue antibody method. However, these methods either require genetic engineering of the
target protein or non-covalent interactions of fairly large antibodies for highlighting the
location of the target biomolecules.
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One method for the delivery of a small molecule probes to a protein target is
through the application of photochemically activated moieties that utilize small molecules
to target proteins and then covalently modify the protein of interest for downstream
analysis8,9,10. In particular, there are three classes of commonly used photoreactive
moieties that allow for photo-crosslinking to proteins, which include aryl azides,
diazirines, and substituted benzophenones. Each of these functional groups is chemicallyinert under dark conditions but can revert to a reactive species by the application of high
energy, ultraviolet light. Upon photo-activation, azides and diazirine groups produce a
nitrene-like or a carbene intermediate, respectively, while benzophenones depend on
radical aryl ketylintermediates for reactivity11,12. However, the reactivity of these
compounds is difficult to tune and often react with the solubilizing media or buffer,
thereby reducing their labeling efficiency.
Recently, there has been the development of multifunctional probes that allow for
traceless labeling of endogenous proteins13,14,15. As discussed in Chapters 3 and 4, these
probes consist of a ligand for binding to the target protein, a fluorophore for visualization,
and some electrophilic moiety that forms a new covalent bond with the target upon
binding to the protein. Generally, the native nucleophile is the sulfhydryl of cysteine that
is intrinsic to the target protein and the small molecule-based electrophile contains a
maleimide for selective bioconjugation to this residue. While these probes offer many
advantages in terms of their size and their ability to be ‘traceless’, they all are limited by
the electrophile delivered to the biological system and electrophiles are known to react
with off-target nucleophiles16. Here, we report the development of a small,
photoactivated, electrophilic moiety that is compatible with aqueous buffer.
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This chapter will focus on a method to photoinitiate the release of 2-chloro-N,Ndimethylethylamine; a molecule that is similar in reactivity to the nitrogen mustard
alkylating agent bis(2-chloroethyl) ethylamine (HN1). This particular compound is
known to form the promiscuous N,N-dialkylaziridinium electrophile under biologicallyrelevant conditions17,18,19. In addition, the N,N-dialkylaziridinium ion formed from HN1
has been implicated in the alkylation of biological nucleophiles, most commonly the
guanine of DNA after exposure to this nitrogen mustard. We reasoned that the formation
of N,N-dimethylaziridinium from 2-chloro-N,N-dimethylethylamine can be initiated with
light if we were to chemically mask the important lone pair of electrons on the tertiary
amine of the latter in the form of a photoreleasable quaternary amine from molecule 2
(Scheme 5.1). The photocage we chose to employ is the 4-methyl-7-methoxycoumarin
chromophore for a number of reasons: (1) this chromophore will undergo heterolytic
bond cleavage resulting in the release of a tertiary amine in neutral form with the lone
pair of electrons made available for subsequent ring closure. (2) the coumarin can be
activated by either ultraviolet light or two-photon infrared light which could allow for
more precise spatial control of labeling and, (3) the quantum yield of release from this
chromophore is highly efficient20. The N,N-dimethylaziridinium that is formed is
expected to be relatively long lived in biological conditions. Reports on similar
aziridinium species suggest that the half-life of the aziridinium in phosphate buffered
saline solution (PBS) at 37˚C is about 70 minutes21.
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Scheme 5.1. Photo-induced aziridinium formation and subsequent alkylation of the
pyridine-based nucleophile, NBP.

5.2 Experimental methods
The caged molecule 2 was synthesized by alkylating N,N-dimethylaminoethanol
with 4-chloromethyl-7-methoxycoumarin22 to form 1 in 72% yield followed by
substitution of the hydroxyl with chloride using thionyl chloride to afford 2 in 81% yield
(Scheme

5.2).

To

explore

the

photoinitiated

release

of

the

2-chloro-N,N-

dimethylethylamine and the subsequent formation of an aziridinium ion, we employed a
colorimetric assay to determine nucleophile alkylation. 4-Nitrobenzylpyridine (NBP) has
been utilized as a detector of alkylation in the literature because N-alkylation and facile
work-up produces a deep purple color that is easy to quantify using a UV/Vis
spectrophotometer23,24. The pyridinium nitrogen is quarternized by the electrophile and
under basic work up a benzylic proton is removed, which conjugates the aryl rings to
produce a deep purple color that can be rapidly measured (Scheme 5.1). We used this
method of analysis to follow the evolution of N,N-dimethylaziridinium formation of the
70

non-caged 2-chloro-N,N-dimethylethylamine, the caged molecule 2 kept in the dark, and
of the caged molecule after exposure to a short pulse of 365 nm light from an LED light
source. In addition, 2-chloro-N,N-dimethylethylamine and caged 2 were incubated with
four amino acids (cysteine, lysine, serine, and arginine) that are biologically relevant
nucleophiles at physiological pH and temperature. We chose these amino acids to give
insight to protein labeling studies that can be done in the future. The 2-chloro-N,Ndimethylethylamine and caged 2 were allowed to react with each amino acid and the
reaction was analyzed by LC/MS to determine the extent of labeling.

Scheme 5.2. Synthesis of caged N,N-dimethylaziridinium precursor 2.

5.3 Results and Discussion
5.3.1 NBP alkylation assay
Our investigation began with the measurement of aziridinium formation from 2chloro-N,N-dimethylethylamine (hydrochloride) in aqueous buffer in the presence of
NBP at 37˚C and pH 7.4. We decided to perform these reactions at physiological pH and
temperature due to our future plans to employ this photochemistry on live mammalian
cells. We followed the time course of NBP alkylation by removing aliquots of the
reaction mixture and incubating them with stop solution followed by ethyl acetate
extraction of the colored product (Figure 5.1). The OD535 of the ethyl acetate layer was
then quantified and all data points were measured in triplicate from three different
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reaction runs. In parallel, we prepared an identical solution of compound 2 and allowed it
to react with the NBP in the dark. We expected some background reactivity due to SN2
displacement of the alkyl chloride on the caged molecule by the nucleophilic pyridine.
However, the caged molecule did not react at a detectable level, suggesting that the
quarternization of the tertiary amine is sufficient to eliminate much of the electrophilic
character of this alkyl chloride (Figure 5.2). Upon photoinitiated release of 2-chloro-N,Ndimethylethylamine from the coumarin cage, NBP alkylation was observed and was quite
similar in reaction rate to the non-caged 2-chloro-N,N dimethylethylamine. The
photoinitiated release of 2-chloro-N,N-dimethylethylamine allows the aziridinium
formation to begin at a prescribed time and results in identical alkylation of the NBP
reporter molecule.

Figure 5.1. Rate of NBP alkylation. Data points represent average of three independent
experiments (n=3 for each experiment) of reaction between alkylating molecule and NBP
following work-up and analysis. Lines are calculated as exponential associations. Green
circles are for 2-chloro-N,N-dimethylethylamine, black boxes are for caged molecule 2
maintained in the dark, and purple triangles are for caged molecule 2 (at the same
concentration and quantity as that used for the green circles) after exposure to 1 min of
365 nm light as represented by purple bar at 60 min mark.
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Figure 5.2. Photographs of alkylation reactions post-workup. (a) 2-chloro N,Ndimethylethylamine incubated with NBP at 30 min, (b) caged molecule 2 irradiated at
365 nm for 1 min and incubated with NBP for 30 min, and (c) caged molecule 2 kept in
the dark with NBP at 30 min. The top, color-containing layer is the ethyl acetate extract
that is normally analyzed via UV/vis.

5.3.2 Mass spectroscopy analysis
Next, we investigated the selectivity of the photo-initiated release of 2-chloroN,N-dimethylethylamine towards four amino acids that represent biologically-relevant
potential nucleophiles. The N-terminus of the amino acids were Fmoc-protected to
discourage the alkylation of the free amine versus the side chain functional groups. As a
positive control, 2-chloro-N,N-dimethylethylamine hydrochloride was incubated with
Fmoc-serine, lysine, arginine, or cysteine for 2 hours at 37˚C and pH 7.4 in 2.5 mL of
PBS/DMSO (4:1) solution. After incubation, 50 μL of the reaction mixture was diluted to
1 mL in methanol and analyzed by LC/MS. Under these conditions only cysteine was
found to be alkylated by 2-chloro-N,N-dimethylethylamine (MW = 415.2). Likewise,
caged 2 was incubated with of each Fmoc-protected amino acid under the same
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conditions in the dark and after irradiation with UV light. After 2 hours of incubation, the
mass corresponding to the alkylated amino acids were not found for caged 2 with no UV
irradiation. In addition, the mass corresponding to unreacted caged 2 was present,
indicating that the cage was not reactive to the buffer at a detectible level. However,
following exposure to 1 min of 365 nm light, the mass corresponding to the alkylated
amino acids was only found in the case of cysteine (MW = 415.2). This finding parallels
the results from the positive control experiment with 2-chloro-N,N-dimethylethylamine.

5.4 Conclusion
In summary, we have developed a convenient method for the photoinitiated
release

of

the

electrophile

N,N-dimethylaziridinium

from

2-chloro-N,N-

dimethylethylamine in situ. While our data does not conclusively confirm the production
of the aziridinium moiety, we have shown that our caged molecule is unreactive before
the release with light. Going forward, we plan to synthesize a similar molecule that
contains a ligand and a propargyl handle to allow for the electrophilic attachment to a
protein of interest. This alkyne will allow for a subsequent [3+2] cyclization (click
reaction) with an azido-based fluorophore or biotin. The present molecular system that is
the subject of this chapter is chemically-inert when kept in the dark and is stable in PBS
solution for >30 days at room temperature. The reactive species is only generated after
light is applied to unmask the tertiary amine. The application of this technology to protein
labeling studies could offer new tools to spatially limit protein modification for the
purpose of protein tracking on cells. The technology will also add another versatile tool
to the arsenal of spatially and temporarily controlled protein labeling bioorganic
chemistry.
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5.5 Material and Methods
5.5.1 General information
All reagents were purchased through Fisher Scientific (Fair Lawn, NJ, USA).
Merck silica gel (35–70 mesh) was used for flash chromatography. NMR spectra were
recorded on a 400 MHz Bruker NMR spectrometer using the residual proton resonance of
the solvent as the standard for proton spectra and the carbon signal of the deuterated
solved as the internal standard for carbon spectra. Chemical shifts are reported in parts
per million (ppm). When peak multiplicities are given, the following abbreviations are
used: s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Mass
spectra were measured on a Waters ZQ device for LRMS while HRMS data was
collected at the University of Massachusetts Mass Facility which is supported, in part, by
the National Science Foundation. The colorimetric absorption measurements were made
on an Evolution 100 UV/Vis spectrometer.

5.5.2 Synthesis of caged electrophile
Synthesis

of

2-Hydroxy-N-((7-methoxy-2-oxo-2Hchromen-4-yl)methyl)-N,N-

dimethylethanaminium (1)
To a stirred solution of 4-chloromethyl-7-methoxycoumarin (500 mg, 2.23
mmol), prepared according to a previous report22 in methanol (15 mL) was added N,Ndimethylethanolamine (896 μL, 8.92 mmol). The reaction mixture was heated to reflux
and allowed to stir for 24 hours. The reaction mixture was cooled to room temperature
and the solvent was removed via rotary evaporation. The crude product was dissolved in
a minimal amount of hot methanol (4 mL) and hexanes were added slowly until 503 mg
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(72% yield) of a white solid precipitated. The solid was collected by filtration and was
rinsed with hexanes and used without further purification.
1

H NMR (400 MHz, D2O) δ ppm = 7.78 (ds, J = 9.09, 2.53 Hz, 1H) 6.99 (dd J = 9.09,

2.53 Hz, 1H) 6.95 (d, J = 2.53 Hz, 1H) 6.58 (s, 1H) 4.73–4.76 (m, 2H) 4.03–4.09 (m, 2H)
3.83 (s, 3H) 3.59–3.64 (m, 2H) 3.13 (s, 6H).
13

C NMR (400 MHz, D2O) δ = 163.32, 162.62, 155.31, 142.70, 126.19, 119.26, 113.48,

112.22, 101.64, 67.30, 62.53, 56.03, 55.49, 51.46.
HRMS (FAB+) Calcd for C15H20NO4 [M+]: 278.1387. Found: 278.1389.
Synthesis

of

2-chloro-N-((7-methoxy-2-oxo-2H-chromen-4-yl)methyl)-N,N-

dimethylethanaminium (2)
To the previously-produced alcohol 1 (100 mg, 0.319 mmol) was added thionyl
chloride (2.0 mL, 28 mmol) and the solution stirred at room temperature for 16 hours.
The volatiles were removed via rotary evaporation followed by high vacuum to leave a
white solid that was recrystallized from isopropanol to yield 86 mg (81% yield) of a
white solid.
1

H NMR (400 MHz, D2O) δ ppm = 7.79 (d, J = 8.59 Hz, 1H) 6.97–7.05 (m, 2H) 6.58 (s,

1H) 4.76 (s, 2H) 4.00–4.07 (m, 2 H) 3.86–3.92 (m, 2H) 3.84 (s, 3H) 3.17 (s, 6H).
13

C NMR (400 MHz, D2O) δ = 163.39, 162.47, 155.31, 142.26, 126.10, 119.36, 113.52,

112.10, 101.68, 66.18, 62.58, 56.05, 51.23, 35.38.
HRMS (FAB+) Calcd for C15H19ClNO3 [M+]: 296.1048. Found: 296.1059.

5.5.3 Photolysis and NBP alkylation assay conditions
All solutions were kept in the dark (aluminum foil wrapped) except during UV
irradiation conditions. Solutions of 2-chloro-N,N-dimethylethylamine or caged molecule
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2

were

prepared

by

dissolving

the

hydrochloride

salt

of

2-chloro-N,N-

dimethylethylamine or the chloride salt of 2 in PBS buffer to a final concentration of 25
mM. Nitrobenzylpyridine solution was prepared in dry acetone to a final concentration of
25 mM. Alkylation assays were performed by mixing 1.0 mL of PBS, 500 μL of test
solution containing either 2 or 2-chloro-N,N-dimethylethylamine, and 500 μL of NBP
solution and allowing them to incubate at 37˚C. Aliquots of the reaction mixture (100 μL)
were removed at various times and were immediately quenched by the addition of 400 μL
ethyl acetate, 500 μL of water, and 63 μL of 1.0 M aqueous KOH. Mixtures were
vortexed for 1 minute and centrifuged to efficiently separate the layers. The organic layer
was removed via pipette and was either directly analyzed by UV absorption or, if highly
colored, diluted 10x or 100x in order to produce OD535 measurements between 0.0 and
1.0 AU. Each sample was measured after zeroing the UV/Vis detector to pure ethyl
acetate and each data point was measured in triplicate. Each data point used in the time
course plot is defined by three separate reactions, aliquot removal, and workup.
Photolysis of the protecting group was accomplished by irradiating the sample from the
top of an open 1 dram vial with the light from a LedEngin High Power LED 365 nm
source (Mouser Electronics, Mansfield, TX, USA) situated 5 mm from the top of the vial
driven by 600 mA of current.

5.5.4 Mass spectrometry analysis of amino acid labeling assay
Stock solutions of the corresponding Fmoc-protected amino acids (Lys, Ser, Cys,
Arg) were dissolved in DMSO to a final concentration of 14 mM. Control experiments
were conducted by dissolving the hydrochloride salt of 2-chloro-N,N-dimethylethylamine
(0.007 mmol) in 200 μL of PBS followed by the addition of 50 μL of the amino acid
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DMSO solution for a final concentration of 28 and 2.8 mM, respectively. Each reaction
was conducted at pH 7.4 and 37˚C for 2 hours at which time a 50 μL aliquot was
removed, diluted to 1 mL in methanol, and analyzed by mass spectrometry. In similar
fashion, caged 2 was dissolved in 200 μL of PBS followed by the addition of 50 μL of
each amino acid DMSO solution and allowed to react for 2 hours at 37˚C and pH 7.4 in
the dark. The reaction mixture was then analyzed as previously described. Lastly, for the
photolysis experiment, caged 2 was dissolved in 200 μL of PBS followed by the addition
of 50 μL of each amino acid DMSO solution and warmed to 37˚C. The sample was
irradiated for 1 min from a LedEngin High Power LED 365 nm source and then allowed
to react for 2 hours at 37˚C and pH 7.4. The reaction mixture was analyzed as previously
described.
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CHAPTER 6
FUTURE DIRECTIONS

6.1 Nanoprobe development
The alkyne nanoprobe discussed in Chapter 4 provides a method for facile
synthesis of a multifunctional probe that could be targeted to a variety of receptors. To
explore the modular nature of this probe further, several portions of the probe can be
altered to develop a kit for fluorescent labeling of endogenous proteins. In this chapter
there will be a discussion of the synthesis of a new ligand for targeting NMDA receptors,
new fluorophore combinations with the probe, and an exploration of linker length for the
acrylamide electrophile.

6.1.1 Ifenprodil-based NMDA receptor targeting
We

have

previously

developed

an

azido-analogue

of

ketamine

for

functionalization of the alkyne nanoprobe, which would give specificity for postsynaptic
NMDA receptors. Another pharmacophore that targets a subclass of NMDA receptors is
the drug ifenprodil. Ifenprodil is a lead compound for a major class of antagonists of the
NMDA receptor with marked selectivity for the NR2B unit. To date, there have been
several studies to characterize its subtype-specific binding to NMDA receptors both in
vitro and in vivo1,2,3,4. The NR2B containing NMDA receptors are particularly interesting
to study because they are preferentially enriched in extrasynaptic sites and may
participate in processes linked to glutamatergic overstimulation, which can cause
excitotoxicity5. Therefore, NR2B-selective antagonists are quite attractive for the
development of therapeutic agents for neuroprotection6.
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Ifenprodil contains two asymmetric centers that give rise to two diastereoisomeric
forms, threo (R*R*) and the erythro (R*S*) forms seen in Figure 6.1. The threo racemate
was found to be five times more potent neuroprotective agent than the erythro
diastereomer in an in vitro glutamate neurotoxicity test2. Investigation of the interaction
of ifenprodil on NMDA receptors places the binding site at the N-terminal domain of the
NR2B unit. The potency of this compound is due to the key structural elements that
incorporate a phenolic aromatic ring connected to a second phenyl ring through a linker
containing a tertiary amine7,8,9. The piperazine ring provides a scaffold to hold the two
aryl rings in an optimum orientation in the binding site, which contain a lipophilic pocket
to accommodates the phenyl ring and a hydrophobic pocket that accepts the phenol
group10.

Figure 6.1. Structures of ifenprodil and fluorescent analogue by Marchand et al10
Work done by Marachand et al. utilized ifenprodil as a ligand for the development
of small molecule fluorescent probes to characterize the microenvironment of the binding
site at the NMDA receptor (Figure 6.1)10. The authors determined that chemical
modification of the benzylic hydroxyl moiety for the attachment of linkers is preferable
to the modification on the phenol moiety due to a hydrogen bond of the benzylic
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hydroxyl with a glutamine residue from NR2B. In addition, a linker bearing a secondary
amine or amide functional group was necessary to maintain affinity for the NMDA
receptor11. Using this information, we have designed two azido-containing analogues of
ifenprodil to react with the alkyne nanoprobe to create a multifunctional probe that will
target NMDA receptors containing the NR2B subunit.
The first azido-analogue compound 4 can be synthesized in two steps starting
from compound 1, which was provided by Dr. Doug Johnson at Pfizer Neuroscience
(Cambridge, MA). Compound 1 was converted to the azido compound 3 according to a
stereospecific mesylation/amination sequence through the use of 6-azidohexan-1-amine
(2), which was synthesized from the corresponding 1,6-diazidohexane. This
transformation occurs with a retention of configuration as a result of a mechanism with
anchimeric assistance due to the in situ formation of an aziridinium intermediate10.
Acidic deprotection of the benzyl protected phenol is expected to yield the azidoanalogue 4 (Scheme 6.1).

Scheme 6.1. Synthesis of ifenprodil azido-analogue 4.
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The second azido-analogue compound 7 can be synthesized in three steps starting
from compound 1. Under similar reaction conditions used previously, compound 1 will
be reacted with mono-Boc protected hexyldiamine to produce intermediate 5. Acid
deprotection of compound 5 is expected to yield amine compound 6, which can react
with 6-azidohexanoic acid under standard peptide coupling conditions to obtain the
azido-analogue 7 (Scheme 6.2).

Scheme 6.2. Synthesis of ifenprodil azido-analogue 7.
Using the rhodamine linked alkyne nanoprobe synthesized previously, we could
develop two NMDA receptor probes specific for the NR2B subunit by utilizing click
chemistry with azido-analogues 4 and 7 (Scheme 6.3). Although the pharmacophore is
the same in both cases, the linker length is varied by 6 carbons. This would allow us to
determine the effects of linker length on binding affinity and provide insight into which
probe would be more useful for visualization of the NMDA receptors.
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Scheme 6.3. Synthesis of ifenprodil based nanoprobes for the NMDA receptor

6.1.2 Fluorophore modification
Another site on the alkyne nanoprobe scaffold for potential modification is the
addition of different fluorophores to allow for visualization of receptors with different
colors or photochemical properties. Changing the fluorophore will allow for pulse-chase
experiments, single molecule imaging, and if the fluorophore is pH or otherwise
environmentally sensitive, can provide information about the surrounding environment.
There are a multitude of commercially available fluorophores that are amine-terminated,
or are easily modified with an amine linker. Of these available fluorophores, several have
been used to visualize receptors of interest both in vitro and in vivo12,13,14. We can
synthesize several fluorescent nanoprobes starting from the alkyne nanoprobe scaffold
through peptide coupling with a fluorophore with an amine linker (Figure 6.2). This will
allow for a fluorescent library of these compounds that can easily be modified with a
pharmacophore utilizing click chemistry, as seen in Chapter 4.
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Figure 6.2. Fluorescent analogues for conjugation to the alkyne nanoprobe

6.1.3 Electrophile linker length
An area of chemical space on the nanoprobe scaffold that has not been evaluated
is the length of the linker containing the acrylamide electrophile. Previously, we have
discussed the effect on changing the pharmacophore for targeting different receptors of
interest or changing the fluorophore used to visualize the receptor. The linker length
between the pharmacophore and the alkyne scaffold is important because it will affect the
binding affinity of the probe for the receptor being studied. However, the linker length for
the electrophile also needs to be considered in case there are no endogenous nucleophiles
in the chemical space of the linker with six carbons. The alkyne nanoprobe scaffold can
be redesigned to contain an electrophile with a short 3 carbon linker derived from 3aminopropanoic acid or a much longer 12 carbon linker derived from 12aminododecanoic acid (Figure 6.3). Varying the linker length of the electrophile, coupled
with different fluorophores discussed in previous section will allow for a kit of these
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alkyne nanoprobes that can be applied to various receptors of interest. If there was a
situation where the pharmacophore used did not lead to labeling of the receptor, now
there will be more options to optimize conditions for binding and crosslinking of the
probe.

Figure 6.3. Linker length modification of alkyne nanoprobe

6.2 Caged alkyne electrophile development
The caged aziridinium compound discussed in Chapter 5 allowed for control of
the alkylation of nucleophiles using UV light. Although the aziridinium compound that
was generated could be visualized using a colormetric assay, it would be difficult to
monitor electrophilic addition to a protein of interest. Going forward, we will synthesize
a similar caged compound as discussed before; however, this new molecule will contain
an alkyne handle for click reactions with a fluorophore or biotin-azide. This new
molecule can be used for protein labeling and could possibly be used as a new core for
future iterations of the nanoprobe technology. In essence, this new labeling technology
would be a hybrid between caged compounds and photoaffinity labeling.
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The synthesis of the caged alkyne electrophile 11 can be completed in 3 steps
from 2-(methylamino)ethanol. 2-(methylamino)ethanol will be alkylated with propargyl
bromide to yield compound 8. Compound 8 will be used in a reaction with thionyl
chloride to form the control alkyne-chloro compound 9, as well as to alkylate 4chloromethyl-7-methoxycoumarin under reflux conditions to yield caged compound 10.
The synthesis of caged compound 11 is then completed following the reaction of caged
compound 10 with thionyl chloride to form the alkyl chloride compound 11 (Scheme
6.4).

Scheme 6.4. Synthesis of a caged alkyne nitrogen mustard
To determine whether the addition of the propargyl handle will have an effect on
aziridinium formation, compound 9 was tested in a NBP alkylation assay to determine if
it will act similarly to the 2-chloro-N,N-dimethylethylamine control compound from the
previous study. As shown in Figure 6.4, the alkyne electrophile was able to alkylate NBP,
which show similar results as the 2-chloro-N,N-dimethylethylamine compound used
before15. In addition, compound 8 was unable to alkylate NBP because it contains an
alcohol moiety instead of an alkyl chloride like the other two compound tested. This
suggests that compound 9 is still able to form an aziridinium intermediate and may
possibly be rendered inert following addition to the coumarin photocage. Further studies
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with both compound 9 and caged compound 11 should determine if this technology can
be utilized to spatially limit protein modification for the purpose of protein tracking on
cells.

Figure 6.4. NBP alkylation assay for alkyne mustard. Left) 2-chloro-N,Ndimethylethylamine Center) Compound 9. Right) Compound 8.
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CHAPTER 7
SUPPLEMENTARY INFORMATION
Table 7.1 List of abbreviations
1-ethyl-3-(3-dimethylamino EDC
propyl)carbodiimide

N,N-Diisopropylethylamine DIPEA
N,N-Dimethylformamide

DMF

N-methyl-D-aspartate

NMDA

Nitrobenzodiazole

NBD

Photoaffinity labeling

PAL

Potassium carbonate
α-amino-3-hydroxy-5-methyl AMPA
4-isoxazolepropioic acid

K2CO3

Potassium iodide

KI

Chinese hamster ovaries

CHO

Potassium tert-butoxide

KOTBu

Central nervous system

CNS

Serotonin transporter

SERT

Dichloromethane

CH2Cl2

Sodium azide

NaN3

Dimethyl sulfoxide

DMSO

Sodium bicarbonate

NaHCO3

Dopamine transporter

DAT

Sodium hydroxide

NaOH

Endoplasmic reticulum

ER

Sodium nitrite

NaNO2

Ethanol

EtOH

Thin layer chromatography

TLC

Ethyl acetate

EtoAc

Thionyl chloride

SOCl2

Hydrochloric acid

HCl

Tin (II) chloride

SnCl2

Hydroxybenzotriazole

HOBt

Triethylamine

Et3N

Magnesium sulfate

MgSO4

Trifluoroacetic acid

TFA

Methanesulfonyl chloride

MsCl

Water

H2O

Mitochondrion-associated
ER membrane

MAM

1,3-di(2-toyl)guanidine

DTG

4-nitrobenzylpyridine

NBP

Acetonitrile

CH3CN

Amyloid lateral sclerosis

ALS
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7.1 Mass spectroscopy data
LC-MS data for DAT nanoprobe (SM-V-61)

LC-MS data for SERT nanoprobe (SM-V-37)

LC-MS data for ketamine nanoprobe (SM-V-127)
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High resolution mass spectroscopy of DAT nanoprobe (SM-V-61)
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High resolution mass spectroscopy of SERT nanoprobe (SM-V-37)

94

High resolution mass spectroscopy of ketamine nanoprobe (SM-V-127)
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